Hims & Hers Health (HIMS) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity Registrant Name	HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38986
Entity Tax Identification Number	98-1482650
Entity Address, Address Line One	2269 Chestnut Street, #523
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94123
City Area Code	415
Local Phone Number	851-0195
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	HIMS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001773751
Current Fiscal Year End Date	--12-31
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		195,535,515
Common Class V
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		8,377,623

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 64,772	$ 27,344
Short-term investments	187,653	72,864
Inventory	10,858	3,543
Prepaid expenses and other current assets	10,950	5,404
Deferred transaction costs	0	3,929
Total current assets	274,233	113,084
Restricted cash	856	1,006
Other long-term assets	7,167	4,548
Intangibles, net	26,932	59
Goodwill	110,881	0
Total assets	420,069	118,697
Current liabilities:
Accounts payable	16,094	8,066
Accrued liabilities	11,206	4,984
Deferred revenue	1,993	1,272
Earn-out liabilities	23,205	0
Warrant liabilities	0	906
Total current liabilities	52,498	15,228
Earn-out liabilities	11,200	0
Other long-term liabilities	1,218	381
Total liabilities	64,916	15,609
Commitments and contingencies (Note 12)
Mezzanine equity:
Redeemable convertible preferred stock par value $0.0001, 275,000,000 and 95,997,674 shares authorized and nil and 93,328,118 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively; liquidation preference of nil and $268,452 as of September 30, 2021 and December 31, 2020, respectively	0	249,962
Stockholders' equity (deficit):
Common stock – Class A shares, par value $0.0001, 2,750,000,000 and 166,696,759 shares authorized and 195,439,626 and 46,025,754 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of September 30, 2021; Class F shares, par value $0.0001, 6,941,352 shares authorized, issued, and outstanding as of December 31, 2020	20	0
Additional paid-in capital	602,975	24,429
Accumulated other comprehensive loss	(52)	(11)
Accumulated deficit	(247,790)	(171,292)
Total stockholders' equity (deficit)	355,153	(146,874)
Total liabilities, mezzanine equity, and stockholders' equity (deficit)	$ 420,069	$ 118,697

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Mezzanine equity:
Mezzanine equity, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Mezzanine equity, shares authorized (in shares)	275,000,000	95,997,674
Mezzanine equity, shares issued (in shares)	0	93,328,118
Mezzanine equity, shares outstanding (in shares)	0	93,328,118
Mezzanine equity, liquidation preference	$ 0	$ 268,452,000
Common Class A
Stockholders' equity (deficit):
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,750,000,000	166,696,759
Common stock, shares issued (in shares)	195,439,626	46,025,754
Common stock, shares outstanding (in shares)	195,439,626	46,025,754
Common Class V
Stockholders' equity (deficit):
Common stock, par value (in dollars per share)	$ 0.0001
Common stock, shares authorized (in shares)	10,000,000
Common stock, shares issued (in shares)	8,377,623
Common stock, shares outstanding (in shares)	8,377,623
Common Class F
Stockholders' equity (deficit):
Common stock, par value (in dollars per share)		$ 0.0001
Common stock, shares authorized (in shares)		6,941,352
Common stock, shares issued (in shares)		6,941,352
Common stock, shares outstanding (in shares)		6,941,352

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 74,173	$ 41,324	$ 187,179	$ 107,291
Cost of revenue	19,301	10,047	44,783	29,733
Gross profit	54,872	31,277	142,396	77,558
Operating expenses:
Marketing	38,293	15,102	93,195	39,675
Selling, general, and administrative	44,240	19,496	142,678	48,401
Total operating expenses	82,533	34,598	235,873	88,076
Loss from operations	(27,661)	(3,321)	(93,477)	(10,518)
Other income (expense):
Change in fair value of liabilities	8,328	(2,527)	13,610	(2,477)
Interest expense	0	0	0	(10)
Other income, net	219	8	320	223
Total other income (expense), net	8,547	(2,519)	13,930	(2,264)
Loss before income taxes	(19,114)	(5,840)	(79,547)	(12,782)
Benefit (provision) for income taxes	3,173	(31)	3,049	(103)
Net loss	(15,941)	(5,871)	(76,498)	(12,885)
Other comprehensive (loss) income	(12)	6	(41)	(12)
Total comprehensive loss	$ (15,953)	$ (5,865)	$ (76,539)	$ (12,897)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.08)	$ (0.16)	$ (0.42)	$ (0.36)
Diluted (in dollars per share)	$ (0.08)	$ (0.16)	$ (0.42)	$ (0.36)
Weighted average shares outstanding:
Basic (in shares)	200,038,761	35,614,598	181,867,522	35,345,972
Diluted (in shares)	200,038,761	35,614,598	181,867,522	35,345,972

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	PIPE Investment	Class A Common Stock Warrants	Common Stock	Common StockPIPE Investment	Common StockClass A Common Stock Warrants	Additional Paid-In Capital	Additional Paid-In CapitalPIPE Investment	Additional Paid-In CapitalClass A Common Stock Warrants	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Redeemable Convertible Preferred Stock	Redeemable Class A Common Stock	Previously Reported	Previously ReportedCommon Stock	Previously ReportedAdditional Paid-In Capital	Previously ReportedAccumulated Other Comprehensive Income (Loss)	Previously ReportedAccumulated Deficit	Previously ReportedRedeemable Convertible Preferred Stock	Previously ReportedRedeemable Class A Common Stock	Revision of Prior Period, Adjustment	Revision of Prior Period, AdjustmentCommon Stock	Revision of Prior Period, AdjustmentAdditional Paid-In Capital	Revision of Prior Period, AdjustmentRedeemable Convertible Preferred Stock	Revision of Prior Period, AdjustmentRedeemable Class A Common Stock
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2019												84,514,191	737,058						186,573,651	1,627,132				(102,059,460)	(890,074)
Mezzanine equity, beginning balance at Dec. 31, 2019												$ 186,741	$ 4,500						$ 186,741	$ 4,500
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)												4,537,700
Issuance of Series D convertible preferred stock, net of issuance costs												$ 31,511
Conversion of convertible securities (in shares)													(737,058)
Conversion of convertible securities													$ (4,500)
Mezzanine equity, ending balance (in shares) at Mar. 31, 2020												89,051,891	0
Mezzanine equity, ending balance at Mar. 31, 2020												$ 218,252	$ 0
Beginning balance (in shares) at Dec. 31, 2019				51,588,612											113,887,093							(62,298,481)
Beginning balance at Dec. 31, 2019	$ (139,793)			$ 0			$ 13,383			$ 2	$ (153,178)			$ (139,793)	$ 0	$ 13,383	$ 2	$ (153,178)			$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of preferred stock to common stock (in shares)				737,058
Conversion of preferred stock to common stock	4,500						4,500
Exercise of vested stock options (in shares)				226
Early exercise of unvested stock options (in shares)				226
Vesting of early-exercised stock options	11						11
Forfeiture of unvested early exercised shares (in shares)				(46,242)
Stock-based compensation	1,404						1,404
Other comprehensive loss	(42)									(42)
Net loss	(6,033)										(6,033)
Ending balance (in shares) at Mar. 31, 2020				52,279,880
Ending balance at Mar. 31, 2020	(139,953)			$ 0			19,298			(40)	(159,211)
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2019												84,514,191	737,058						186,573,651	1,627,132				(102,059,460)	(890,074)
Mezzanine equity, beginning balance at Dec. 31, 2019												$ 186,741	$ 4,500						$ 186,741	$ 4,500
Mezzanine equity, ending balance (in shares) at Sep. 30, 2020												92,850,809	0
Mezzanine equity, ending balance at Sep. 30, 2020												$ 245,168	$ 0
Beginning balance (in shares) at Dec. 31, 2019				51,588,612											113,887,093							(62,298,481)
Beginning balance at Dec. 31, 2019	(139,793)			$ 0			13,383			2	(153,178)			(139,793)	$ 0	13,383	2	(153,178)			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	(12)
Net loss	(12,885)
Ending balance (in shares) at Sep. 30, 2020				52,073,334
Ending balance at Sep. 30, 2020	$ (143,341)			$ 0			22,732			(10)	(166,063)
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2019												84,514,191	737,058						186,573,651	1,627,132				(102,059,460)	(890,074)
Mezzanine equity, beginning balance at Dec. 31, 2019												$ 186,741	$ 4,500						$ 186,741	$ 4,500
Mezzanine equity, ending balance (in shares) at Dec. 31, 2020	93,328,118											93,328,118	0						206,031,290	0				(112,703,172)
Mezzanine equity, ending balance at Dec. 31, 2020	$ 249,962											$ 249,962	$ 0						$ 249,962	$ 0
Beginning balance (in shares) at Dec. 31, 2019				51,588,612											113,887,093							(62,298,481)
Beginning balance at Dec. 31, 2019	(139,793)			$ 0			13,383			2	(153,178)			(139,793)	$ 0	13,383	2	(153,178)			0
Ending balance (in shares) at Dec. 31, 2020				52,967,106											116,930,602							(63,963,496)
Ending balance at Dec. 31, 2020	(146,874)			$ 5			24,424			(11)	(171,292)			(146,874)	$ 0	24,429	(11)	(171,292)			0	$ 5	$ (5)
Mezzanine equity, beginning balance (in shares) at Mar. 31, 2020												89,051,891	0
Mezzanine equity, beginning balance at Mar. 31, 2020												$ 218,252	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)												868,768
Issuance of Series D convertible preferred stock, net of issuance costs												$ 6,028
Exercise of Series C convertible preferred stock warrants (in shares)												583,632
Exercise of Series C convertible preferred stock warrants												$ 3,852
Mezzanine equity, ending balance (in shares) at Jun. 30, 2020												90,504,291	0
Mezzanine equity, ending balance at Jun. 30, 2020												$ 228,132	$ 0
Beginning balance (in shares) at Mar. 31, 2020				52,279,880
Beginning balance at Mar. 31, 2020	(139,953)			$ 0			19,298			(40)	(159,211)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of vested stock options (in shares)				15,043
Exercise of vested stock options	27						27
Early exercise of unvested stock options (in shares)				10,438
Vesting of early-exercised stock options	9						9
Forfeiture of unvested early exercised shares (in shares)				(509,602)
Stock-based compensation	1,925						1,925
Other comprehensive loss	24									24
Net loss	(981)										(981)
Ending balance (in shares) at Jun. 30, 2020				51,795,759
Ending balance at Jun. 30, 2020	(138,949)			$ 0			21,259			(16)	(160,192)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)												2,065,594
Issuance of Series D convertible preferred stock, net of issuance costs												$ 14,361
Exercise of Series C convertible preferred stock warrants (in shares)												280,924
Exercise of Series C convertible preferred stock warrants												$ 2,675
Mezzanine equity, ending balance (in shares) at Sep. 30, 2020												92,850,809	0
Mezzanine equity, ending balance at Sep. 30, 2020												$ 245,168	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of Class A common stock warrants (in shares)				143,452
Exercise of Class A common stock warrants	8						8
Exercise of vested stock options (in shares)				122,810
Exercise of vested stock options	44						44
Early exercise of unvested stock options (in shares)				11,313
Vesting of early-exercised stock options	7						7
Stock-based compensation	1,414						1,414
Other comprehensive loss	6									6
Net loss	(5,871)										(5,871)
Ending balance (in shares) at Sep. 30, 2020				52,073,334
Ending balance at Sep. 30, 2020	$ (143,341)			$ 0			22,732			(10)	(166,063)
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2020	93,328,118											93,328,118	0						206,031,290	0				(112,703,172)
Mezzanine equity, beginning balance at Dec. 31, 2020	$ 249,962											$ 249,962	$ 0						$ 249,962	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)												(206,511)
Pre-closing stock repurchase, net of exercise of vested options												$ (125)
Conversion of convertible securities (in shares)												(93,121,607)
Conversion of convertible securities												$ (249,837)
Mezzanine equity, ending balance (in shares) at Mar. 31, 2021												0	0
Mezzanine equity, ending balance at Mar. 31, 2021												$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2020				52,967,106											116,930,602							(63,963,496)
Beginning balance at Dec. 31, 2020	(146,874)			$ 5			24,424			(11)	(171,292)			(146,874)	$ 0	24,429	(11)	(171,292)			0	$ 5	(5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)				(1,817,519)
Pre-closing stock repurchase, net of exercise of vested options	(21,902)						(21,902)
Conversion of preferred stock to common stock (in shares)				93,121,607		1,867,292
Conversion of preferred stock to common stock	249,837		$ 21,678	$ 9			249,828		$ 21,678
Repayment of related-party promissory notes associated with vested shares	854						854
Forfeiture of related-party promissory notes (in shares)				(370,734)
Conversion of Series D preferred stock warrants to Class A common warrants	1,160						1,160
Issuance of common stock upon Merger, net of transaction costs and merger warrant liability (in shares)				23,892,244
Issuance of common stock upon Merger, net of transaction costs of $16.2 million	129,659			$ 2			129,657
Issuance of PIPE shares (in shares)					7,500,000
Issuance of PIPE shares		$ 75,000			$ 1			$ 74,999
Issuance of earn-out shares to common stockholders (in shares)				14,153,520
Issuance of earn-out shares to common stockholders	1			$ 1
Exercise of vested stock options (in shares)				37,887
Exercise of vested stock options	80						80
Vesting of early-exercised stock options	54						54
Warrant expense in connection with Merger	154						154
Stock-based compensation	34,230						34,230
Other comprehensive loss	(61)									(61)
Net loss	(51,404)										(51,404)
Ending balance (in shares) at Mar. 31, 2021				191,351,403
Ending balance at Mar. 31, 2021	$ 292,466			$ 18			515,216			(72)	(222,696)
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2020	93,328,118											93,328,118	0						206,031,290	0				(112,703,172)
Mezzanine equity, beginning balance at Dec. 31, 2020	$ 249,962											$ 249,962	$ 0						$ 249,962	$ 0
Mezzanine equity, ending balance (in shares) at Sep. 30, 2021	0											0	0
Mezzanine equity, ending balance at Sep. 30, 2021	$ 0											$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2020				52,967,106											116,930,602							(63,963,496)
Beginning balance at Dec. 31, 2020	(146,874)			$ 5			24,424			(11)	(171,292)			$ (146,874)	$ 0	$ 24,429	$ (11)	$ (171,292)			$ 0	$ 5	$ (5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	(41)
Net loss	(76,498)
Ending balance (in shares) at Sep. 30, 2021				203,817,249
Ending balance at Sep. 30, 2021	355,153			$ 20			602,975			(52)	(247,790)
Mezzanine equity, beginning balance (in shares) at Mar. 31, 2021												0	0
Mezzanine equity, beginning balance at Mar. 31, 2021												$ 0	$ 0
Mezzanine equity, ending balance (in shares) at Jun. 30, 2021												0	0
Mezzanine equity, ending balance at Jun. 30, 2021												$ 0	$ 0
Beginning balance (in shares) at Mar. 31, 2021				191,351,403
Beginning balance at Mar. 31, 2021	292,466			$ 18			515,216			(72)	(222,696)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of preferred stock to common stock (in shares)						88
Conversion of preferred stock to common stock			1						1
Issuance of common stock upon vesting of RSUs, net of tax withholdings (in shares)				725,740
Issuance of common stock upon vesting of RSUs, net of tax withholdings	(1,958)			$ 1			(1,959)
Issuance of common stock upon Merger, net of transaction costs and merger warrant liability (in shares)				250,000
Issuance of common stock for acquisition of business (in shares)				624,880
Issuance of common stock for acquisition of business	1,949						1,949
Exercise of vested stock options (in shares)				294,374
Exercise of vested stock options	178						178
Vesting of early exercised stock options, net of cancellations (in shares)				(2,643)
Vesting of early-exercised stock options	48						48
Stock-based compensation	9,491						9,491
Other comprehensive loss	32									32
Net loss	(9,153)										(9,153)
Ending balance (in shares) at Jun. 30, 2021				193,243,842
Ending balance at Jun. 30, 2021	$ 293,054			$ 19			524,924			(40)	(231,849)
Mezzanine equity, ending balance (in shares) at Sep. 30, 2021	0											0	0
Mezzanine equity, ending balance at Sep. 30, 2021	$ 0											$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of preferred stock to common stock (in shares)						1,958,615
Conversion of preferred stock to common stock			$ 16,967						$ 16,967
Issuance of common stock upon vesting of RSUs, net of tax withholdings (in shares)				159,247
Issuance of common stock upon vesting of RSUs, net of tax withholdings	(651)						(651)
Issuance of common stock for acquisition of business (in shares)				8,074,935
Issuance of common stock for acquisition of business	50,665			$ 1			50,664
Exercise of vested stock options (in shares)				380,779
Exercise of vested stock options	313						313
Vesting of early exercised stock options, net of cancellations (in shares)				(169)
Vesting of early-exercised stock options	41						41
Stock-based compensation	10,717						10,717
Other comprehensive loss	(12)									(12)
Net loss	(15,941)										(15,941)
Ending balance (in shares) at Sep. 30, 2021				203,817,249
Ending balance at Sep. 30, 2021	$ 355,153			$ 20			$ 602,975			$ (52)	$ (247,790)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficit (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 16.2	$ 2.5	$ 0.1

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (76,498)	$ (12,885)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,445	692
Stock-based compensation	55,259	4,743
Change in fair value of liabilities	(13,610)	2,477
Warrant expense in connection with Merger	154	0
Lease termination expense	0	1,846
Amortization of debt issuance costs	144	251
Net amortization on securities	1,732	21
Benefit for deferred taxes	(3,178)	0
Non-cash other	871	0
Changes in operating assets and liabilities:
Inventory	(6,928)	(735)
Prepaid expenses and other current assets	2,635	37
Other long-term assets	(58)	777
Accounts payable	6,306	(897)
Accrued liabilities	(794)	1,149
Deferred revenue	217	(65)
Other long-term liabilities	(4)	379
Net cash used in operating activities	(31,307)	(2,210)
Investing activities
Purchases of investments	(219,361)	(84,015)
Maturities of investments	99,375	43,790
Proceeds from sales of investments	3,465	11,550
Acquisition of businesses, net of cash acquired	(46,468)	0
Investment in website development and internal-use software	(3,242)	(1,651)
Purchases of property, equipment, and intangible assets	(279)	(1,293)
Net cash used in investing activities	(166,510)	(31,619)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock	0	51,927
Pre-closing stock repurchase	(22,027)	0
Proceeds from issuance of common stock upon Merger	197,686	0
Proceeds from PIPE	75,000	0
Payments for transaction costs	(12,851)	(2,074)
Proceeds from repayment of promissory notes associated with vested and unvested shares	1,193	0
Proceeds from exercise of Class A common stock warrants, net of redemption payments	787	0
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations	567	111
Repayments of principal on term loan	0	(1,515)
Payments for taxes related to net share settlement of equity awards	(5,234)	0
Net cash provided by financing activities	235,121	48,449
Foreign currency effect on cash and cash equivalents	(26)	(11)
Increase in cash, cash equivalents, and restricted cash	37,278	14,609
Cash, cash equivalents, and restricted cash at beginning of period	28,350	22,797
Cash, cash equivalents, and restricted cash at end of period	65,628	37,406
Supplemental disclosures of cash flow information
Cash paid for taxes	279	246
Cash paid for interest	0	10
Non-cash investing and financing activities
Expiration of Class A common stock redemption right	0	4,500
Exercise of convertible preferred stock warrants	0	6,508
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase	125	0
Conversion of redeemable convertible preferred stock to common stock	249,837	0
Assumption of Merger warrants liability	51,814	0
Redemption/exercise of Class A common stock warrants	37,834	0
Reclassification of deferred transaction costs	3,929	0
Conversion of Series D preferred stock warrants to Class A common warrants	1,160	0
Deferred transaction costs payable	0	577
Purchase of property and equipment included in accounts payable	0	35
Change in transaction costs payable	568	0
Vesting of early-exercised stock options	147	27
Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses	99,958	0
Equity awards classified as prepaid expenses	$ 2,625	$ 0

Organization

Organization	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Hims & Hers Health, Inc. (the “Company”), formerly known as Oaktree Acquisition Corp. (“OAC”), is a direct-to-customer telehealth company incorporated in Delaware. The Company’s mission is to make healthcare accessible, affordable, and convenient for everyone. The Company designed and built a digitally native, cloud-based technology centered around the consumer, and designed everything with the consumer in mind. The Company’s proprietary websites, telehealth platform, electronic medical records system, and pharmacy integration combine to provide customers with a seamless, easy-to-use, digital-first experience. The Company offers a range of health and wellness products and services available for purchase directly by customers on the Company’s websites, the Company’s mobile application starting in November 2021, and through wholesale partners. On January 20, 2021 (the “Closing Date”), OAC completed the acquisition of Hims, Inc. (“Hims”) pursuant to the Agreement and Plan of Merger dated as of September 30, 2020 (the “Merger Agreement”) by and among OAC, Hims, and Rx Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of OAC (“Merger Sub”). The Merger Agreement provided for, among other things, the combination of Hims and OAC pursuant to the merger of Merger Sub with and into Hims, with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”). The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the unaudited condensed consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims is the predecessor to the Company. The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Merger (0.4530 shares of Company Class A common stock for 1 share of Hims Class A common stock). Prior to the Merger, OAC ordinary shares and warrants were traded on the New York Stock Exchange (“NYSE”) under the ticker symbols “OAC” and “OAC WS”, respectively. On the Closing Date, the Company’s Class A common stock and warrants began trading on the NYSE under the ticker symbols “HIMS” and “HIMS WS”, respectively. One of the primary purposes of the Merger was to provide a platform for Hims to gain access to the U.S. capital markets. See Note 3 – Recapitalization for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of September 30, 2021 are unaudited. The condensed consolidated balance sheet as of December 31, 2020, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2020 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the periods presented, but are not necessarily indicative of the results expected for the full fiscal year or any other period. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements. For the three and nine months ended September 30, 2021 and 2020, the Company had operations primarily in the United States and immaterial operations in the United Kingdom. Except for the addition of business combinations to the Company’s significant accounting policies, there have been no changes to the Company’s significant accounting policies described in the audited consolidated financial statements for the year ended December 31, 2020, that have had a material impact on these condensed consolidated financial statements and related notes. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation and recognition of warrants, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, valuation of earn-out liabilities, and estimates in capitalization of website development and internal-use software costs. Management believes that the estimates and judgments upon which it relies, are reasonable based upon information available to it at the time that these estimates and judgments were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s condensed consolidated financial statements will be affected. Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s condensed consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Segment Reporting The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio. In 2020, the Company also had cash collateral for use of the financial institution’s cash management services. See Note 11 – Borrowing Arrangements for further details. Total cash, cash equivalents, and restricted cash are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash and cash equivalents $ 64,772 $ 27,344 Restricted cash 856 1,006 Total cash, cash equivalents, and restricted cash $ 65,628 $ 28,350 Investments Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments at or close to maturity. The investments, if any, are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive income (loss) on the condensed consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense) on the condensed consolidated statements of operations and comprehensive loss. Inventory Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold. Revenue Recognition The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. Revenue consists of the following (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Online $ 72,032 $ 38,829 $ 180,858 $ 100,637 Wholesale 2,141 2,495 6,321 6,654 Total revenue $ 74,173 $ 41,324 $ 187,179 $ 107,291 For online revenue, the Company defines its customer as an individual who purchases products or services through websites. For wholesale revenue, the Company defines its customer as a wholesale partner. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus margin-based estimates. For each of the three and nine months ended September 30, 2021 and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups”, which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 9 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with certain affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company has made an accounting policy election to account for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following fiscal period. For wholesale arrangements, payments are collected in accordance with contract terms. Stock-Based Compensation The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s Chief Executive Officer (“CEO”) with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur. Warrant Liabilities The Company classifies Private Placement Warrants and Public Warrants (both defined and discussed in Note 15 – Common Stock), and warrants to purchase preferred stock as liabilities (discussed in Note 14 – Redeemable Convertible Preferred Stock) . At the end of each reporting period, changes in fair value during the period are recognized as a component of other income (expense) within the condensed consolidated statements of operations and comprehensive loss. Warrant liabilities are adjusted for changes in fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants. Since all liability-classified warrants were exercised or redeemed as of September 30, 2021, the associated warrant liabilities were reclassified to additional paid-in capital. Recently Adopted Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act. This classification allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, and the Company has elected to use adoption dates applicable to private companies. The Company will lose its EGC status on December 31, 2021 and qualify as a large accelerated filer based on its market capitalization as of June 30, 2021, according to Rule 12b-2 of the Securities Exchange Act of 1934, as amended. As a result, the Company will adopt all accounting pronouncements currently deferred under the EGC election according to public company standards beginning with its Annual Report on Form 10-K for the year ending December 31, 2021 (“2021 Annual Report”), including interim period disclosures within that filing. The adoption dates for the new accounting pronouncements disclosed below have been presented accordingly. In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment . ASU 2017-04 simplifies the accounting for goodwill impairments by eliminating the requirement to compare the implied fair value of goodwill with its carrying amount as part of step two of the goodwill impairment test referenced in ASC 350, Intangibles – Goodwill and Other . As a result, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. However, the impairment loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for smaller reporting companies for annual reporting periods beginning after December 15, 2022, including any interim impairment tests within those annual periods, with early application permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. In January 2021, the Company elected to early adopt ASU 2017-04, and the adoption had no impact on the consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement , which amends ASC 820, Fair Value Measurement . This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2019, with early adoption permitted for removed disclosures and delayed adoption until fiscal year 2020 permitted for the new disclosures. The Company adopted this disclosure requirement for the year ended December 31, 2020 and disclosures are presented accordingly. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which requires lessees to recognize leases on their balance sheets and disclose key information about leasing arrangements. The ASU establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition on the income statement. In July 2018, the FASB approved an amendment to the new guidance that allows companies the option of using the effective date of the new standard as the initial application (at the beginning of the period in which it is adopted, rather than at the beginning of the earliest comparative period) and to recognize the effects of applying the new ASU as a cumulative effect adjustment to the opening balance sheet or retained earnings. ASU 2016-12 is effective for annual periods beginning after December 15, 2018 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual and interim periods beginning after December 15, 2021, with early adoption permitted. The Company plans to adopt Topic 842 for the 2021 Annual Report. The Company is still evaluating the adoption approach as well as the impact of adopting this ASU, and expects to report increased assets and liabilities as a result of recording ROU assets and lease liabilities. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments to require the measurement of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance also amended the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on such debt security is a credit loss. The standard is effective for nonpublic companies for annual and interim periods beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company does not expect the impact of the adoption of this ASU to be material. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which is intended to improve consistency and simplify several areas of existing guidance. ASU 2019-12 removes certain exceptions to the general principles related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company is still evaluating the impact of the adoption of this ASU and does not expect the impact to be material. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The guidance includes amendments to improve the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to the financial statements is codified in the disclosure section of the codification and to clarify guidance so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company does not expect the impact of the adoption of this ASU to be material.

Recapitalization

Recapitalization	9 Months Ended
	Sep. 30, 2021
Reverse Recapitalization [Abstract]
Recapitalization	Recapitalization As discussed in Note 1 – Organization, on the Closing Date, OAC completed the acquisition of Hims and acquired 100% of Hims’ shares and Hims received gross proceeds of $197.7 million. Transaction costs of $18.7 million, which consist of legal, accounting, and other professional services directly related to the Merger, are included in additional paid-in capital on the condensed consolidated balance sheet. On the Closing Date, each Hims stockholder received approximately 0.4530 shares of the Company’s Class A common stock, par value $0.0001 per share, for each share of Hims Class A common stock, par value $0.000001 per share, that such stockholder owned (with the CEO receiving 0.4530 shares of Hims & Hers Class V common stock, par value $0.0001 per share, for each share of Hims Class V common stock, par value $0.000001 per share, that the CEO owned). Each Hims stockholder also received 0.0028 warrants exercisable for the Company’s Class A common stock, for each share of Hims Class A or Class V common stock owned by such stockholder prior to the Merger and earn-out shares at an exchange ratio of 0.0443. See Note 14 – Redeemable Convertible Preferred Stock and Note 15 – Common Stock for additional details of the Company’s stockholders’ equity prior to and subsequent to the Merger. As additional consideration, OAC also granted 888,143 OAC Class A common stock warrants (“Parent Warrants”) to Hims’ stockholders, 3,443 Parent Warrants to warrant holders, and approximately 35,000 RSUs to Hims’ option and RSU holders (“Parent Warrant RSUs”). All equity awards of Hims were assumed by OAC and converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 0.4530. Each award of the Hims’ RSUs was converted into RSUs of the Company based on an exchange ratio of 0.4530. Similarly, all outstanding Hims warrants were converted at an exchange ratio of 0.4530. The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Hims was determined to be the accounting acquirer since Hims’ shareholders prior to the Merger had the greatest voting interest in the combined entity, Hims’ shareholders appointed the initial directors of the combined Board of Directors and control future appointments, Hims comprises all of the ongoing operations, and Hims’ senior management directs operations of the combined entity. Accordingly, all historical financial information presented in these unaudited condensed consolidated financial statements represents the accounts of Hims and its wholly-owned subsidiaries as if Hims, rather than OAC, is the predecessor to the Company. No step-up basis of intangible assets or goodwill was recorded and net assets were stated at historical cost consistent with the treatment of the transaction as a reverse recapitalization of Hims. The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (0.4530 Company shares for 1 Hims share). Merger Earn-Out Shares Following the closing of the Merger, holders of Hims’ common stock and outstanding equity awards (including warrant, stock option and RSU holders) had the right to receive up to an aggregate amount of 16,000,000 shares of Company Class A common stock (or equivalent equity award) that would vest (in part) in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period on or prior to the date that is five years following the Closing Date. These shares of restricted Class A common stock and equivalent equity awards would also vest in connection with an acquisition of the Company if the applicable thresholds were met in any sale (as defined in the Merger Agreement) but subject to the same five-year deadline. In February 2021, all earn-out thresholds were met. In the first quarter of 2021, earn-out awards related to option holders received final approval by the Board of Directors. The earn-out shares are equity classified since they do not meet the liability classification criteria outlined in ASC 480, Distinguishing Liabilities from Equity and are both (i) indexed to the Company’s own shares and (ii) meet the criteria for equity classification. PIPE Investment Concurrently with the execution of the Merger Agreement, OAC entered into subscription agreements on September 30, 2020 with certain investors (the “PIPE Investors”) pursuant to which such investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million (the “PIPE Investment”). The PIPE Investment was consummated substantially concurrently with the closing of the Merger.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions The Company completed two acquisitions in 2021 and accounted for these transactions using the acquisition method with the purchase price being allocated to tangible and identifiable intangible assets acquired and liabilities assumed based on their respective estimated fair values on the acquisition date. Fair values were determined using income approaches. The purchase price allocation was prepared on a preliminary basis and may be subject to further adjustments as additional information becomes available concerning the fair value of the assets acquired and liabilities assumed. Honest Health Limited In June 2021, the Company acquired all of the outstanding equity of Honest Health Limited (“HHL”), an entity located in the United Kingdom that offers health and wellness products and services, to further expand its operations in the United Kingdom. The purchase price for accounting purposes was $4.8 million, including cash paid upfront and payable in the future, an aggregate of 624,880 shares of the Company’s Class A common stock valued at $1.9 million, and contingent consideration of $1.2 million. The purchase agreement includes up to $10.0 million of potential earn-out payable upon achievement of revenue targets, which is recognized as contingent consideration as well as post-acquisition employment expense. The purchase price for accounting purposes excludes stock and cash consideration to be paid by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 13 – Stock-Based Compensation for additional details. The Company also incurred acquisition costs of $1.8 million directly related to the acquisition, which were recorded within selling, general, and administrative expenses on the condensed consolidated statements of operations and comprehensive loss. The following table summarizes the preliminary acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 Amortization expense related to identified intangible assets, which include trade name, developed technology, and customer relationships, is recognized on a straight-line basis over the assets’ useful lives of two The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $2.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. or U.K. income tax purposes. The pro forma financial information, assuming the acquisition had occurred as of the beginning of the fiscal year prior to the fiscal year of the acquisition, as well as the revenue and earnings generated during the period after the acquisition date, were not material and accordingly have not been presented. Apostrophe In July 2021, the Company acquired all of the outstanding equity of YoDerm, Inc. (“Apostrophe”) , an entity located in the United States that offers health and wellness products and services. The purchase price for accounting purposes was $131.6 million, including cash payment of $48.2 million, an aggregate of 8,074,935 shares of the Company’s Class A common stock valued at $50.7 million, and contingent consideration of $32.7 million. The purchase agreement includes up to $50.0 million of potential earn-out payable upon achievement of revenue targets, which is recognized as contingent consideration as well as post-acquisition employment expense. The purchase price for accounting purposes excludes stock consideration issued by the Company that is subject to vesting, which is recognized as selling, general, and administrative expenses post-acquisition. See Note 13 – Stock-Based Compensation for additional details . The Company also incurred acquisition costs of $4.9 million directly related to the acquisition, which were recorded within selling, general, and administrative expenses on the condensed consolidated statements of operations and comprehensive loss. The following table summarizes the preliminary acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636 The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate. Amortization expense related to identified intangible assets, which include trade name, developed technology, and customer relationships, is recognized on a straight-line basis over the assets’ useful lives of two The excess of the consideration paid over the fair value of the net assets acquired is recorded as goodwill. The acquired goodwill of $108.1 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recognized upon acquisition is not expected to be deductible for U.S. income tax purposes. From the acquisition date through September 30, 2021, the Company recognized revenue related to Apostrophe of approximately $5 million. Incremental pro forma revenue attributed to Apostrophe, assuming the acquisition had occurred as of January 1, 2020, would have been approximately $5 million and $3 million for the three months ended September 30, 2021 and 2020, and approximately $15 million and $9 million for the nine months ended September 30, 2021 and 2020. The unaudited pro forma revenue is presented for informational purposes only and does not purport to be indicative of the results of future operations or the results that would have occurred had the transaction taken place on January 1, 2020. Pro forma earnings of Apostrophe, assuming the acquisition had occurred as of January 1, 2020, as well as earnings generated during the period after the acquisition date, were not material and accordingly have not been presented.

Investments

Investments	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Short-term investments as of September 30, 2021, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 149,606 $ 1 $ (12) $ 149,595 Government bonds 15,499 — — 15,499 Asset-backed bonds 22,559 1 (1) 22,559 Total short-term investments $ 187,664 $ 2 $ (13) $ 187,653 Short-term investments as of December 31, 2020, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 55,224 $ 5 $ (2) $ 55,227 Government bonds 14,121 2 — 14,123 Asset-backed bonds 3,514 — — 3,514 Total short-term investments $ 72,859 $ 7 $ (2) $ 72,864

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): September 30, December 31, Finished goods $ 9,230 $ 2,856 Raw materials 1,628 687 Total inventory $ 10,858 $ 3,543

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Trade and other receivables, net $ 1,324 $ 1,147 Prepaid expenses 8,910 2,691 Other current assets 716 1,566 Total prepaid expenses and other current assets $ 10,950 $ 5,404

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): September 30, December 31, Marketing expenses $ 4,344 $ 1,122 Payroll costs 3,101 919 Professional services 866 1,241 Tax payables 755 651 Warrant exercise deposit liability — 664 Other accrued liabilities 2,140 387 Total accrued liabilities $ 11,206 $ 4,984

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities In order for customers to obtain a prescription product, customers must complete a consultation with a Provider on the Company’s websites through one of the Affiliated Medical Groups and receive a written prescription by the applicable Provider. The Affiliated Medical Groups and the Company do not have any shareholders in common. The Affiliated Medical Groups are 100% owned by licensed Providers. The Company is party to service agreements with the Affiliated Medical Groups pursuant to which the Company provides management and administrative services and collects the medical consultation fees from customers on behalf of the Affiliated Medical Groups. In October 2020, the Company also entered into service agreements with XeCare LLC (“XeCare”), a licensed mail order pharmacy affiliated with the Company which provides prescription fulfillment services solely to the Company’s customers. Similarly, as part of the Apostrophe acquisition discussed in Note 4 – Acquisitions, the Company entered into service agreements with Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, together with XeCare, the “Affiliated Pharmacies”), which also provides prescription fulfillment services solely to the Company’s customers. The Affiliated Medical Groups and Affiliated Pharmacies are legal entities that the Company has determined qualify as variable interest entities (“VIEs”). The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s condensed consolidated financial statements. As of September 30, 2021 and December 31, 2020, the Company’s condensed consolidated balance sheets included current and total assets of $1.5 million and $1.4 million for the VIEs. As of September 30, 2021 and December 31, 2020, current liabilities were $1.4 million and $0.8 million and total liabilities were $1.8 million and $1.2 million. All amounts are after elimination of intercompany transactions and balances. The results of operations and cash flows of the VIEs are included in the Company’s condensed consolidated financial statements. For the three months ended September 30, 2021 and 2020, the VIEs charged the Company $7.2 million and $5.6 million for services rendered. For the nine months ended September 30, 2021 and 2020, the VIEs charged the Company $14.8 million and $9.2 million for services rendered. For the three months ended September 30, 2021 and 2020, operations of the VIEs generated a net loss of $0.7 million and net income of $1.4 million inclusive of administrative expenses. For the nine months ended September 30, 2021 and 2020, operations of the VIEs generated net losses of $3.6 million and $0.7 million inclusive of administrative expenses.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 57,575 $ — $ — $ 57,575 Government bonds — 3,024 — 3,024 Short-term investments: Corporate bonds — 149,595 — 149,595 Government bonds — 15,499 — 15,499 Asset-backed bonds — 22,559 — 22,559 Restricted cash: Money market funds 856 — — 856 Total assets $ 58,431 $ 190,677 $ — $ 249,108 Liabilities Earn-out liabilities, current — — 23,205 23,205 Earn-out liabilities, long-term — — 11,200 11,200 Total liabilities $ — $ — $ 34,405 $ 34,405 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 12,163 $ — $ — $ 12,163 Government bonds — 12,693 — 12,693 Short-term investments: Corporate bonds — 55,227 — 55,227 Government bonds — 14,123 — 14,123 Asset-backed bonds — 3,514 — 3,514 Restricted cash: Money market funds 1,006 — — 1,006 Total assets $ 13,169 $ 85,557 $ — $ 98,726 Liabilities Warrant liabilities $ — $ — $ 906 $ 906 Total liabilities $ — $ — $ 906 $ 906 The fair values of cash, accounts receivable, accounts payable, and accrued liabilities approximated their carrying values as of September 30, 2021 and December 31, 2020, due to their short-term nature. All other financial instruments except for warrant liabilities related to the preferred stock warrants, Private Placement Warrants, and earn-out liabilities are valued either based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The warrant liabilities related to the preferred stock warrants and Private Placement Warrants contain significant unobservable inputs including the expected term and with respect to the preferred stock warrants, the share exchange ratio in evaluating the fair value of underlying common stock and exercise price. Therefore, warrant liabilities associated with the preferred stock warrants and Private Placement Warrants were evaluated to be Level 3 fair value measurements. As of December 31, 2020, the Company used a BSM option-pricing model to determine the value of the outstanding Series D preferred stock warrants (that replaced the Series C preferred stock warrants as discussed in Note 11 – Borrowing Arrangements). Subsequent to the Merger, the Series D preferred stock warrants were converted to Class A common stock warrants and recognized in additional paid-in capital as a result of the conversion to equity-classified Class A common stock warrants. For the nine months ended September 30, 2021, changes in warrant liabilities were primarily related to changes in liabilities for warrants assumed as part of the recapitalization, including Private Placement Warrants and Public Warrants (defined and discussed in Note 15 – Common Stock). The Company valued the Private Placement Warrants using a Monte Carlo valuation simulation. Inherent in a Monte Carlo simulation are assumptions related to expected term, volatility, risk-free interest rate, and dividend yield. The expected term of the warrants was determined to be equivalent to their remaining contractual term and includes consideration of the redemption features that were incorporated into the Monte Carlo model. The Company derived the volatility of its Class A common stock based on average historical stock volatilities of a peer group of public companies that the Company considers to be comparable to its business over a period equivalent to the expected term of the Private Placement Warrants. The risk-free interest rate is based on the U.S. Treasury’s rates of U.S. Treasury zero-coupon bonds with a maturity similar to the expected term of the Private Placement Warrants. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following assumptions were used for the valuation of the Private Placement Warrants on the settlement date: Expected term 0.16 Volatility 65.0 % Risk-free rate — % Dividend yield — % The Public Warrants were valued using the listed trading price on the relevant settlement date. On July 9, 2021, the Company called the Public Warrants and the Parent Warrants for redemption. Refer to Note 15 – Common Stock for additional detail. The change in the fair value of warrant liabilities is as follows (in thousands): Balance at December 31, 2020 $ 906 Conversion of Series D preferred stock warrants to Class A common stock warrants (1,160) Private Placement Warrants and Public Warrants 51,814 Redeemed/exercised warrants (37,859) Change in fair value (13,701) Balance at September 30, 2021 $ — As of September 30, 2021, the Company had no transfers between levels of the fair value hierarchy of its assets or liabilities measured at fair value. Due to the exercise and conversion to Class A common stock warrants of all preferred stock warrants and exercise of all of the Private Placement Warrants during the period, there were no longer any Level 3 warrant liabilities. The Company used Level 3 fair value measurements when determining earn-out liabilities as well as intangible assets obtained in the acquisitions of HHL and Apostrophe. The fair value of the earn-out liabilities associated with the acquisitions of HHL and Apostrophe were determined based on revenue projections and probability of achievement of revenue targets as evaluated using a Monte Carlo simulation. This is considered a Level 3 fair value measurement containing significant unobservable inputs including estimates of achieving the revenue targets. The undiscounted range of contingent purchase consideration is nil to $3.3 million for HHL, and nil to $49.4 million for Apostrophe. The following assumptions were used to determine the fair value: HHL Apostrophe Revenue risk-adjusted discount rate 9.1 % 4.9 % Revenue volatility 50.0 % 50.0 % Counterparty discount rate 5.0 % 5.0 % The fair value of the earn-out liabilities is remeasured at each reporting period. This change in fair value is related to contingent consideration as well as compensation costs (see Note 13 – Stock-Based Compensation) and is recognized in selling, general, and administrative expense on the condensed consolidated statements of operations and comprehensive loss. The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2020 $ — HHL acquisition 1,208 Apostrophe acquisition 32,650 Change in fair value due to revaluation and service-based vesting 547 Balance at September 30, 2021 $ 34,405

Borrowing Arrangements

Borrowing Arrangements	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Borrowing Arrangements	Borrowing Arrangements Silicon Valley Bank Under the Second Amended and Restated Loan Agreement dated November 27, 2019, between Hims and Silicon Valley Bank (“SVB”), upon Hims’ request, SVB would issue letters of credit (the “Letters of Credit”) in an aggregate amount not to exceed $2.0 million. This amount is reduced by the amount otherwise available with respect to the cash management services, which may include merchant services, direct deposit of payroll, business credit card, and check cashing services identified in SVB’s various agreements. On September 30, 2020, Hims entered into the First Loan Modification Agreement (“Loan Modification Agreement”) and the aggregate amount of the Letters of Credit was amended to $3.5 million. As of September 30, 2021, SVB issued on the Company’s behalf, a letter of credit in the amount of $0.8 million as a security deposit for a warehouse space in New Albany, Ohio. SVB required $0.8 million to be maintained as collateral for the outstanding letter of credit. The Company expects to continue to renew the letter of credit through the duration of the lease. As this is for longer than one year, the Company presents the $0.8 million within non-current restricted cash on the consolidated condensed balance sheet. In January 2021, the Company terminated the Second Amended and Restated Loan Agreement with SVB resulting in the release of restricted cash of $0.2 million under the arrangement. The outstanding letter of credit for the warehouse was not included as part of this termination. TriplePoint Venture Growth On November 27, 2019, Hims entered into a Plain English Capital Growth and Security Agreement (the “2019 Capital Agreement”) with TriplePoint Venture Growth (“TPC”) consisting of a term loan in the aggregate principal amount of up to $50.0 million, with $25.0 million being available immediately through December 31, 2020 (the “Part 1 Commitment Amount”), and an additional $25.0 million becoming available upon utilization of the Part 1 Commitment Amount through December 31, 2020. There was no minimum advance amount. As collateral, the Company provided a second lien security interest to TPC of substantially all its assets. As of December 31, 2020, the Company had not drawn down from this term loan and the facility expired. In connection with the 2019 Capital Agreement, the Company issued a warrant to TPC granting TPC the right to purchase 89,747 shares of Hims’ Series C preferred stock at an exercise price of $7.67 per share, subject to adjustment in regard to the preferred stock series, number of shares, and exercise price if the per share price of subsequent preferred stock rounds to less than $7.67. On March 12, 2020, Hims sold Series D preferred stock at an issuance price of $6.96, which triggered an adjustment to the TPC warrant terms per the original agreement, resulting in conversion of the previously issued 89,747 Series C preferred stock warrants at an exercise price of $7.67 into 98,723 Series D preferred stock warrants at an exercise price of $6.96. Subsequent to the Merger, the Series D preferred stock warrants were converted to Class A common stock warrants. Refer to Note 14 – Redeemable Convertible Preferred Stock for further discussion of the conversion into Class A common stock warrants.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases Total rent expense for the three months ended September 30, 2021 and 2020, was $0.3 million and $0.3 million. Total rent expense for the nine months ended September 30, 2021 and 2020, was $1.1 million and $1.7 million. In January 2020, the Company entered into a 63-month non-cancelable lease for 302,880 square feet of warehouse space in New Albany, Ohio. The lease commenced on June 1, 2020. Total minimum lease payments are $7.9 million, net of rent abatement for an initial three-month period and with annual escalation of 2.5%. The Company has the option to extend the lease term for a period of five years. Future minimum lease commitments subsequent to September 30, 2021 are as follows (in thousands): 2021 $ 384 2022 1,559 2023 1,598 2024 1,638 2025 1,114 Total $ 6,293 Purchase Obligations As of September 30, 2021, the Company had contractual obligations to make $2.1 million in purchases related to cloud-based software contracts used in operations. Legal Proceedings From time to time, the Company is a party to various litigation, claims, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, non-monetary sanctions, or relief. Management is not currently aware of any matters that are reasonably likely to have a material adverse impact on the Company’s business, financial position, results of operations, or cash flows.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation 2017 Stock Plan and 2020 Equity Incentive Plan In July 2017, the Company adopted the 2017 Stock Plan (the “2017 Plan”). Under the 2017 Plan, the Board of Directors could grant awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock awards to employees, directors, and consultants. In January 2021, in connection with the Merger, the Board of Directors adopted the 2020 Equity Incentive Plan (the “2020 Plan”) and reserved 21,000,000 authorized shares of Class A common stock the Company could issue. In addition, up to 19,000,000 shares of Hims Class A common stock subject to awards granted under the 2017 Plan that were forfeited, expired or lapsed unexercised or unsettled could be added to the 2020 Plan reserve. Beginning on January 1, 2022 and ending on January 1, 2031, the number of authorized shares of common stock under the 2020 Plan will automatically increase by 5% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year unless the Board of Directors approves a lesser number. As of the effective date of the 2020 Plan, no further stock awards have been or will be granted under the 2017 Plan. During the period, 335,577 shares of Class A common stock subject to awards granted under the 2017 Plan that were outstanding on the Merger date and forfeited after the adoption of the 2020 Plan were added to the 2020 Plan reserve. Therefore, as of September 30, 2021, there were 21,335,577 shares of Class A common stock reserved and 16,418,493 shares of Class A common stock available for the Company to grant under the 2020 Stock Plan; there were no more shares available for grant under the 2017 Plan (since the 2017 Plan was replaced by the 2020 Plan). Under both the 2017 Plan and 2020 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five years from the grant date. Stock Options Options for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date and then 1/48th of the total grant vesting monthly thereafter. Options granted to current employees generally vest 1/48th of the total grant monthly over four years. Options granted are exercisable within a period not exceeding ten years from the grant date. On June 17, 2020, the Board of Directors granted 3,246,139 and 1,623,070 stock options to the CEO with an exercise price of $2.43 to vest upon either (i) an acquisition of the Company with per share consideration equal to at least $22.99 and $38.31, respectively, or (ii) a per share price on a public stock exchange that is at least equal to $22.99 and $38.31, respectively. The CEO is required to be employed at the time the per share consideration/price is achieved in order to receive the awards, but the awards are not subject to any other service condition. The Company recognizes expense related to these awards based on the fair value and derived service term as measured using a Monte Carlo simulation model, but only upon achieving the requirements outlined in (i) and (ii) above. The grant date fair value was $16.6 million for these awards. The $22.99 per share price threshold related to awards for the 3,246,139 stock options was achieved in February 2021 subsequent to the Merger and, therefore, the Company recognized all $11.3 million of expense related to the grant during the three months ended March 31, 2021 due to achievement of the market condition. As of September 30, 2021, there was $3.5 million of remaining compensation expense to be recognized for the remaining 1,623,070 stock options over a period of 2.54 years. In connection with the Merger, each Hims option holder received an equivalent award at an exchange ratio of 0.4530 that vests in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. The grant date fair value of the Company’s stock options granted was estimated using the following weighted average assumptions for the nine months ended September 30, 2021: Expected term (in years) 5.93 Expected volatility 58.6 % Risk-free interest rate 0.9 % Expected dividend yield — % Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2020 26,459 $ 1.16 8.50 $ 131,770 Recapitalization (14,474) 1.41 Outstanding at December 31, 2020 11,985 $ 2.57 8.50 $ 131,770 Granted 1,255 12.69 Exercised (including early exercised options vested during the period) (1,288) 0.73 Forfeited and expired (249) 4.31 Outstanding at September 30, 2021 11,703 3.80 8.09 52,937 Vested and expected to vest as of September 30, 2021 11,703 3.80 8.09 52,937 Exercisable as of September 30, 2021 10,346 2.83 7.92 52,108 The weighted average grant date fair value of options granted for the nine months ended September 30, 2021 was $6.81 per share and the intrinsic value of vested options exercised was $9.2 million. As of September 30, 2021, there was $21.3 million of unrecognized stock-based compensation related to unvested stock options excluding the CEO stock options, which is expected to be recognized over a weighted average period of 3.05 years. The options outstanding and exercisable as of September 30, 2021 (excluding CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life Shares Weighted Average Remaining Contractual Life $ 0.06 – 0.40 2,593 6.46 2,590 6.46 1.55 – 2.33 3,047 7.64 2,910 7.64 2.43 – 3.65 3,254 8.67 3,254 8.67 8.17 – 12.26 1,871 9.31 1,490 9.23 12.79 – 19.19 938 9.55 102 9.45 11,703 10,346 RSUs All RSUs granted prior to the Merger were subject to achievement of a liquidity event which included (i) an initial public offering, (ii) a business combination transaction, or (iii) a sale event as defined by the 2017 Plan. On January 20, 2021, the liquidity event was achieved with the closing of the Merger. RSUs for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date on the first Company Quarterly Vesting Date (defined below) and the remaining grant vesting quarterly thereafter on the specified vesting dates of March 15, June 15, September 15, and December 15 (each, a “Company Quarterly Vesting Date” or collectively, “Company Quarterly Vesting Dates”). Additional RSUs granted to current employees generally vest quarterly on Company Quarterly Vesting Dates over four years. In connection with the Merger, each Hims RSU holder received an equivalent award at an exchange ratio of 0.4530 that vests in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. In addition, all Hims RSU and option holders received (a) earn-out RSUs that would vest in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period, or a Company sale (as defined in the Merger Agreement) occurs and the thresholds are met on or prior to the date that is five years following the Closing Date; and (b) an allocation of Parent Warrant RSUs. All of these RSUs vest in accordance with the terms of the initial RSU and option award, in addition to any of the aforementioned requirements. The earn-out thresholds for earn-out RSUs were all met in February 2021. The earn-out awards are equity classified since they do not meet the liability classification criteria outlined in ASC 480, Distinguishing Liabilities from Equity and are both (i) indexed to the Company’s own shares and (ii) meet criteria for equity classification. The Company determined the fair value of the earn-out RSUs using a Monte Carlo simulation model. The following assumptions were used in this valuation: Expected term (in years) 5.00 Expected volatility 60.0 % Risk-free interest rate 0.5 % Expected dividend yield — % The value of the Company’s equity was also an input into the model and was determined based on the closing trading price of the Company’s Class A common stock on the Closing Date of $16.38. RSU activity including RSUs outstanding prior to the Merger, earn-out RSUs, and Parent Warrant RSUs is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2020 3,480 $ 5.30 Recapitalization (1,904) 5.99 Unvested at December 31, 2020 1,576 11.29 Granted 4,540 12.09 Vested (1,385) 12.76 Forfeited and expired (211) 10.93 Unvested at September 30, 2021 4,520 $ 11.64 Included in the above activity are 476,308 earn-out RSUs and 9,478 Parent Warrant RSUs issued to the CEO as part of the Merger that vest in accordance with the same market conditions as the CEO stock options, of which 317,539 earn-out RSUs and 6,319 Parent Warrant RSUs vested in the period. In addition, the Company granted 45,297 RSUs in 2020 and 4,431 earn-out RSUs and 88 Parent Warrant RSUs as part of the Merger in January 2021 to a non-executive officer that vest in accordance with the achievement of revenue targets upon meeting certain revenue targets from the sale of specific products. None of the awards vested in the period. These grants are also included in the above activity. As of September 30, 2021, there was unrecognized stock-based compensation related to unvested RSUs of $42.5 million, which is expected to be recognized over a weighted average period of 2.96 years. Vendor Warrants Included in stock-based compensation expense is expense for issuance of Class A common stock warrants to nonemployees in connection with vendor service arrangements. In connection with the Merger, warrant holders received (a) an equivalent warrant at an exchange ratio of 0.4530 (which was determined not to result in incremental stock-based compensation expense similar to the evaluations for stock options and RSUs above); (b) the right to receive, upon exercise, earn-out shares that vest in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period, or a Company sale (as defined in the Merger Agreement) occurs and the thresholds are met on or prior to the date that is five years following the Closing Date; and (c) the right to receive, upon exercise, an allocation of Parent Warrants. All of these instruments vest in accordance with the terms of the initial warrant in addition to any of the aforementioned requirements. The earn-out thresholds were all met in February 2021. The earn-out shares and Parent Warrants are equity classified since they do not meet the liability classification criteria. On July 9, 2021, the Company called the Parent Warrants for redemption. Refer to Note 15 – Common Stock for additional detail. Vendor warrant activity, excluding any right to receive Merger consideration, is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Average Exercise Price Weighted Average Contractual Term (in Years) Aggregate Intrinsic Value Outstanding at December 31, 2020 1,861 $ 0.79 7.01 $ 9,957 Recapitalization (1,018) 0.96 Outstanding at December 31, 2020 843 $ 1.75 7.01 $ 9,957 Exercised (381) 1.75 Outstanding at September 30, 2021 462 1.75 7.01 2,677 Vested and expected to vest as of September 30, 2021 462 1.75 7.01 2,677 Exercisable as of September 30, 2021 462 1.75 7.01 2,677 Upon the exercise of outstanding warrants above, vendors also have the right to receive 45,225 shares of Merger consideration, consisting of the holders’ allocation of earn-out consideration. As of September 30, 2021, all stock-based compensation expense related to vendor warrants and associated earn-out shares and Parent Warrants has been recognized. Stock Subject to Vesting and Earn-out Share Liability In June 2021, the Company granted 447,553 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $5.5 million in connection with the acquisition of HHL. As part of the acquisition of HHL, the Company also recognized an earn-out liability based on the achievement of certain revenue targets. A portion of the earn-out liability is expected to be settled in shares of Class A common stock. Vesting of the restricted shares and the earn-out are contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the three and nine months ended September 30, 2021. The expense will be recognized over a four-year vesting period with 25% vesting one year after the acquisition date and the remaining vesting quarterly thereafter. Unrecognized stock-based compensation expense of $5.5 million will be recognized over a weighted average period of 3.58 years. In July 2021, the Company granted 2,332,557 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $24.2 million in connection with the acquisition of Apostrophe. Vesting of the restricted shares is contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the three and nine months ended September 30, 2021. The expense will be recognized over a three-year vesting period with 17% vesting 6 months after the acquisition date and the remaining vesting quarterly thereafter. Unrecognized stock-based compensation expense of $22.2 million will be recognized over a weighted average period of 2.76 years. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Marketing $ 2,328 $ 261 $ 4,946 $ 919 Selling, general, and administrative 9,541 1,153 50,313 3,824 Total stock-based compensation expense $ 11,869 $ 1,414 $ 55,259 $ 4,743 The Company capitalized $0.2 million and $0.5 million of stock-based compensation as internal-use software for the three and nine months ended September 30, 2021. The Company did not capitalize any stock-based compensation as internal-use software for the three and nine months ended September 30, 2020.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock As of December 31, 2020 the Company had authorized 95,997,674 shares of Hims’ convertible preferred stock, designated in series, with the rights and preferences of each designated series to be determined by the Board of Directors. The following table is a summary of Hims’ redeemable convertible preferred stock as of December 31, 2020 (in thousands, except for share data): Series Shares Shares Aggregate Proceeds, Issue Price Series Seed 4,987,477 4,987,477 $ — $ — $ 0.0001 Series A 23,822,492 23,822,492 6,621 5,106 0.2780 Series A-1 5,742,012 5,742,012 753 740 0.1312 Series B 13,270,590 13,270,590 24,600 23,429 1.8538 Series B-1 9,807,952 9,807,952 20,000 14,965 2.0392 Series B-2 13,464,939 13,464,939 51,371 49,911 3.8152 Series C 14,850,340 14,760,594 113,072 92,590 7.6604 Series D 10,051,872 7,472,062 52,035 51,900 6.9639 Total 95,997,674 93,328,118 $ 268,452 $ 238,641 Transactions Related to Convertible Preferred Stock From March to July 2020, a group of investors purchased 7,472,062 shares of Hims Series D redeemable convertible preferred stock and the Company received $51.9 million in net proceeds. In connection with the Merger, all series of Hims redeemable convertible preferred stock were converted into Hims’ Class A common stock on a one-for-one basis and then converted to the Company’s Class A common stock at an exchange ratio of 0.4530. Warrants for Redeemable Convertible Preferred Stock In February 2020, in accordance with the terms outlined in March 2019, the Company issued 1,341,865 Hims Series C convertible preferred stock warrants based on 2019 revenue. The fair market value of the Hims Series C convertible preferred stock warrants was estimated using the BSM option-pricing model, and at the issuance date, fair value of the liability was $10.0 million. The original liability was recorded as an issuance cost for the Hims Series C preferred stock, reducing the value of the Hims Series C proceeds within mezzanine equity on the consolidated balance sheets. Subsequent adjustments to the fair value of the Hims Series C convertible preferred stock warrants were recorded within other income (expense), net on the consolidated statements of operations and comprehensive loss. The holders of the Hims Series C convertible preferred stock exercised all their warrants and purchased 1,341,865 shares of Hims Series C convertible preferred stock from the Company in 2020 resulting in settlement of the Hims Series C convertible preferred stock warrant liability. The Company received less than $0.1 million in net proceeds. Upon exercise, the warrant liability had an estimated fair market value of $11.3 million that was reclassified into convertible preferred stock on the consolidated balance sheet.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Common Stock	Common Stock Prior to the Merger, the Company had two classes of authorized common stock, Hims Class A common stock and Hims Class F common stock. Shares issued on early exercise are not considered outstanding for accounting purposes because the employees holding these awards are not entitled to the rewards of stock ownership. The rights of the holders of Hims Class A and Class F common stock were identical, except with respect to (i) electing members of the Board of Directors and (ii) voting rights. The outstanding shares of Hims Class A and Hims Class F common stock presented on the consolidated balance sheet and on the consolidated statement of mezzanine equity and stockholders’ equity (deficit) for the year ended December 31, 2020 were legally outstanding shares, including shares issued in exchange for related-party promissory notes. Stock Repurchase During 2020, the Company repurchased 85,594 of unvested shares of Hims Class A common stock for a cash payment of less than $0.1 million, which resulted in a reduction of deposit liability from the early exercise of stock options. In addition, in May 2020, an executive officer departed the Company, which resulted in the repurchase of 509,602 unvested shares of Hims Class A common stock in exchange for the cancelation of the principal payable of $0.9 million under an associated promissory note. On January 20, 2021, the Company repurchased from its stockholders and canceled 2,207,580 shares of Hims Class A common stock, including certain stockholders who exercised outstanding stock options, for aggregate payment of $22.0 million. Included within the shares repurchased was 183,548 shares of Hims Class A common stock from the net exercise of stock options as part of the pre-closing stock repurchase for $1.8 million. The repurchase was recognized as a reduction of additional paid-in capital and redeemable convertible preferred stock. Merger Transaction Immediately prior to the Merger, each outstanding share of Hims’ Class F common stock and preferred stock converted into Hims Class A common stock at the then-effective conversion rate. As a result of the Merger, each outstanding share of the Hims capital stock was converted into the right to receive newly issued shares of the Company’s Class A common stock and certain other securities, other than the shares of Hims Class V common stock issued to its CEO immediately prior to the Closing, which were converted into the right to receive newly issued shares of the Company’s Class V common stock and certain other securities. On the Closing Date, each Hims stockholder received approximately 0.4530 shares of the Company’s Class A common stock, par value $0.0001 per share, for each share of Hims Class A common stock, par value $0.000001 per share, that such stockholder owned (with the CEO receiving 0.4530 shares of the Company’s Class V common stock, par value $0.0001 per share, for each share of Hims Class V common stock, par value $0.000001 per share, that the CEO owned). Each stockholder also received 0.0028 warrants exercisable for the Company’s Class A common stock, for each share of Hims Class A or Class V common stock owned by such stockholder prior to the Merger and earn-out shares at an exchange ratio of 0.0443. Settlement of Nonrecourse Related-Party Promissory Notes In connection with the Merger, the obligations due under all nonrecourse related-party promissory notes were satisfied through the aggregate payment of $1.2 million and the aggregate forfeiture of 370,734 shares of the Company’s Class A common stock. PIPE Investment Concurrently with the execution of the Merger Agreement, certain investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million. Class A Common Stock Warrants As discussed above, Class A common stock warrants have been issued in connection with debt agreements (Note 11 – Borrowing Arrangements), vendor service agreements (Note 13 – Stock-Based Compensation), issuance of preferred stock (Note 14 – Redeemable Convertible Preferred Stock ) and to all common stockholders and warrant holders as part of the Merger. Prior to Merger In 2020, Hims Class A common stock warrants were exercised to purchase 1,051,204 shares of Hims Class A common stock at an exercise price range of $0.06 to $1.75 per share. In January 2021, holders of Hims Class A common stock vendor warrants exercised their warrants and purchased 380,746 shares of Hims Class A common stock at an exercise price of $1.75 per share. Subsequent to Merger As the accounting acquirer, Hims was deemed to assume 3,012,500 Class A common stock warrants that were held by Oaktree Acquisition Holdings, L.P. (“Sponsor”) at an exercise price of $11.50 (“Private Placement Warrants”) and 6,708,333 Class A common stock warrants held by OAC’s shareholders at an exercise price of $11.50 (“Public Warrants”) as well as 888,143 Parent Warrants that were granted to Hims’ equity holders as part of the Merger. The Parent Warrants have the same terms as the Public Warrants except they are subject to a lock-up that expired 180 days after the Merger. Subsequent to the Merger, the Private Placement Warrants, Public Warrants, and Parent Warrants for shares of Class A common stock meet liability classification requirements since the warrants may be required to be settled in cash under a tender offer. In addition, Private Placement Warrants are potentially subject to a different settlement amount as a result of being held by the Sponsor which precludes the Private Placement Warrants from being considered indexed to the entity’s own stock. Therefore, these warrants are classified as liabilities on the condensed consolidated balance sheets. Each warrant held by Hims’ stockholders that was unexercised at the time of the Merger was assumed by the Company and represents the right to receive (a) an equivalent warrant at an exchange ratio of 0.4530 (which was determined not to result in incremental expense); (b) the right to receive, upon exercise, earn-out shares that vest in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50 and $20.00 for any 10 trading days within any 20-trading day period, or a Company sale (as defined in the Merger Agreement) occurs and the thresholds are met on or prior to the date that is five years following the Closing Date; and (c) the right to receive, upon exercise, an allocation of Parent Warrants. All of these instruments vest in accordance with the terms of the initial warrant in addition to any of the aforementioned requirements. The earn-out thresholds were all met in February 2021. The earn-out shares are equity classified since they do not meet the liability classification criteria outlined in ASC 480, Distinguishing Liabilities from Equity and are both (i) indexed to the Company’s own shares and (ii) meet criteria for equity classification. In February 2021, all of the outstanding 3,012,500 Private Placement Warrants were net exercised for 1,474,145 shares of Class A common stock. Public Warrants Terms The Public Warrants became exercisable into shares of Class A common stock upon 30 days after the Closing Date. The Public Warrants expire at the later of five years after the completion of a business combination or upon redemption or liquidation. Commencing 90 days after the Public Warrants become exercisable, the Company could redeem all and only all of the Public Warrants: • at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined based on the redemption date at a price equal to the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants; • if the last reported closing price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; • if there is an effective registration statement covering the Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given, or an exemption from registration is available. Upon calling the Public Warrants for redemption, management had the option to require all holders that wished to exercise the Public Warrants to do so on a cashless basis, as described in the warrant agreement. Additionally, in no event was the Company required to net cash settle. Warrant Redemption On July 9, 2021, the Company issued a redemption notice to warrant holders announcing that all Public Warrants and Parent Warrants outstanding on August 9, 2021 at 5:00 p.m. New York City time would be redeemed for $0.10 per warrant, if not earlier exercised on a cash or cashless basis. After July 9, 2021 and prior to redemption, warrant holders were entitled to exercise (i) in cash, at an exercise price of $11.50 per share of Class A common stock or (ii) on a cashless basis in which the exercising holder was entitled to receive 0.267 shares of Class A common stock per warrant. Any warrants not exercised by August 9, 2021 were automatically redeemed by the Company at a price of $0.10 per warrant. In connection with the redemption, 1,958,615 shares of Class A common stock were issued upon exercise of warrants prior to the redemption date and the Company made an immaterial redemption payment to the holders of redeemed warrants. Additionally, the fair value of the warrant liability was reclassified to additional paid-in capital. RSU Releases During the three and nine months ended September 30, 2021, the Company released 248,659 and 1,385,811 gross shares of Class A common stock upon vesting of RSUs. In connection with the releases, 89,412 and 500,824 shares of Class A common stock were withheld for the payment of employee taxes. Shares Issued to Financial Advisor In connection with the Merger, in 2021, the Company issued 250,000 shares of Class A common stock to a financial advisor who provided transaction-related services. Acquisitions As part of the acquisition of HHL, the Company issued 177,327 shares of Class A common stock and an additional 447,553 shares of Class A common stock that are subject to vesting. As part of the acquisition of Apostrophe, the Company issued 5,742,378 shares of Class A common stock and an additional 2,332,557 shares of Class A common stock that are subject to vesting. The shares subject to vesting are considered stock-based compensation as outlined in Note 13 – Stock-Based Compensation.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Atomic Labs, LLC (“Atomic Labs”) is a related-party venture capital startup studio that launched the Company, providing initial capital and governance. An affiliated company of Atomic Labs provides professional services to the Company, primarily to support engineering and operations functions. All services were provided at cost. For the three months ended September 30, 2021 and 2020, the Company recorded a total of $0.8 million and $1.4 million to Atomic Labs and its affiliated company for services performed and costs incurred on behalf of the Company. For the nine months ended September 30, 2021 and 2020, the Company recorded a total of $2.3 million and $2.5 million to Atomic Labs and its affiliated company for services performed and costs incurred on behalf of the Company. In addition, for the three months ended September 30, 2021 and 2020, the Company recorded $0.2 million and less than $0.1 million of expense for services from Vouched, a related-party company that provides identity verification services. For the nine months ended September 30, 2021 and 2020, the Company recorded $0.5 million and $0.1 million of expense for services from Vouched. Nonrecourse Related-Party Promissory Notes As of December 31, 2020, the Company had promissory notes from certain of the Company’s executive officers, as well as a founding employee and an executive chairman. The promissory notes, which were issued to the Company by the related parties as consideration for the exercise of stock options, were considered nonrecourse notes for accounting purposes. The loans were secured by the shares of Hims Class A common stock held by the individuals. There were 16,345,627 shares of Hims Class A common stock securing the related-party promissory notes as of December 31, 2020. The related-party promissory notes bore interest between 2.2% and 3.0% per annum. The loans were due upon the earliest of (1) ten years from the debt issuance date, (2) a liquidation of the Company, or (3) six months following an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended. Prepayment of principal and interest could be made at any time without penalty. The nonrecourse related-party promissory notes are not given accounting effect until the notes are repaid in full as the underlying stock options are not considered exercised for accounting purposes. As of December 31, 2020, the total outstanding balance under these promissory notes was $7.2 million. In connection with the Merger, the obligations due under all nonrecourse related-party promissory notes were satisfied through the receipt of $1.2 million in the aggregate and the forfeiture of an aggregate 370,734 shares of Hims Class A common stock. The related-party promissory notes were settled within additional paid-in capital on the condensed consolidated balance sheet. Redeemable Common Stock Transaction

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share Prior to the Merger and prior to effecting the recapitalization, the Company had two classes of common stock: Hims Class A and Hims Class F common stock. The rights of the holders of Hims Class A and Hims Class F common stock were identical, including the liquidation and dividend rights, except with respect to electing members of the Board of Directors and voting rights. As the liquidation and dividend rights were identical, undistributed earnings and losses were allocated on a proportionate basis and the resulting net loss per share attributable to common stockholders was the same for both Hims Class A and Hims Class F common stock on an individual and combined basis. Subsequent to the Merger, the Company continues to have two classes of common stock: Class A and Class V common stock. Similar to the previous structure, the rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid for the three and nine months ended September 30, 2021 and 2020. Undistributed earnings for each period are allocated to participating securities, including the redeemable convertible preferred stock, based on the contractual participation rights of the security to share in the current earnings as if all current period earnings had been distributed. As there is no contractual obligation for the redeemable convertible preferred stock to share in losses, the Company’s basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average shares of common stock outstanding during periods with undistributed losses. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Class A Class V Class A Class F Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (15,273) $ (668) $ (4,727) $ (1,144) $ (73,219) $ (3,279) $ (10,355) $ (2,530) Denominator: Weighted average shares outstanding, basic and diluted 191,661,138 8,377,623 28,673,246 6,941,352 174,072,957 7,794,565 28,404,620 6,941,352 Basic and diluted net loss per share $ (0.08) $ (0.08) $ (0.16) $ (0.16) $ (0.42) $ (0.42) $ (0.36) $ (0.36) Basic net loss per share is the same as diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2021 and 2020, because the inclusion of potential shares of common stock would have been anti-dilutive for the periods presented. There were no redeemable shares during the three and nine months ended September 30, 2021 and the three months ended September 30, 2020. During the nine months ended September 30, 2020, weighted average Hims Class A common shares presented excludes 220,579 shares subject to redemption. Redeemable shares do not absorb losses. The following table discloses securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 16,345,627 1,168,952 16,570,671 Common stock issued for early exercise of stock options 130,925 191,337 235,766 216,401 Redeemable convertible preferred stock — 92,318,613 6,495,364 89,293,938 Stock options 16,608,921 15,028,510 16,494,336 10,291,433 RSUs 4,447,842 — 3,972,999 — Warrants to purchase Class A common stock 2,773,408 1,793,993 6,199,099 1,861,315 Warrants to purchase redeemable convertible preferred stock — 704,633 — 1,158,407 Common stock issued subject to vesting 2,754,756 — 961,130 —

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Tax	Income Tax The effective income tax rate was 16.6% and (0.5)% for the three months ended September 30, 2021 and 2020 and 3.8% and (0.8)% for the nine months ended September 30, 2021 and 2020 . During the current quarter, the tax rate was impacted by a partial release of valuation allowance totaling $3.1 million as a result of acquisitions. The effective tax rate differs from the U.S. federal rate primarily due to the impacts of the valuation allowance placed on the Company’s deferred tax assets and state minimum taxes.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of September 30, 2021 are unaudited. The condensed consolidated balance sheet as of December 31, 2020, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2020 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the periods presented, but are not necessarily indicative of the results expected for the full fiscal year or any other period.
Consolidation	The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation and recognition of warrants, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, valuation of earn-out liabilities, and estimates in capitalization of website development and internal-use software costs. Management believes that the estimates and judgments upon which it relies, are reasonable based upon information available to it at the time that these estimates and judgments were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s condensed consolidated financial statements will be affected.
Business Combinations	The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s condensed consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations.
Segment Reporting	The Company is managed as a single operating segment on a consolidated basis, inclusive of acquisitions. The Company determined that the Chief Executive Officer (“CEO”) is the chief operating decision maker as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions and managing the organization at a consolidated level.
Cash, Cash Equivalents, and Restricted Cash	The Company considers all highly liquid investments purchased with an original maturity or remaining maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash and cash equivalents with financial institutions. The restricted cash balance comprises cash collateral that is held by the Company’s primary financial institution to secure a letter of credit issued as a security deposit for the Company’s warehouse facility in New Albany, Ohio. In 2020, the Company
Investments	Available-for-sale debt instruments with original maturities at the date of purchase greater than three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt instruments with original maturities at the date of purchase and remaining maturities of greater than one year are classified as long-term investments. The Company intends to sell such investments at or close to maturity. The investments, if any, are designated as available-for-sale and are reported at fair value, with unrealized gains and losses, net of tax, recorded in other comprehensive income (loss) on the condensed consolidated statements of operations and comprehensive loss, except for other-than-temporary impairments. The Company determines the cost of the investment sold based on specific identification at the individual security level. The Company records the interest income and realized gains and losses on the sale of these instruments within other income (expense) on the condensed consolidated statements of operations and comprehensive loss.
Inventory	Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold.
Revenue Recognition	The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus margin-based estimates. For each of the three and nine months ended September 30, 2021 and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups”, which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 9 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with certain affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company has made an accounting policy election to account for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following fiscal period. For wholesale arrangements, payments are collected in accordance with contract terms.
Stock-based Compensation	The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s Chief Executive Officer (“CEO”) with performance and market conditions and earn-out RSUs were valued using the Monte Carlo simulation model. The Company recognizes compensation costs on a straight-line basis over the requisite service period of the employee and vendor, which is generally the vesting term of four years for options, warrants, and RSUs that do not have performance or market conditions. Stock options and RSUs with performance conditions are recognized when it is probable that performance criteria will be achieved and compensation cost is recognized using the accelerated attribution method. The Company accounts for forfeitures as they occur.
Warrant Liabilities	The Company classifies Private Placement Warrants and Public Warrants (both defined and discussed in Note 15 – Common Stock), and warrants to purchase preferred stock as liabilities (discussed in Note 14 – Redeemable Convertible Preferred Stock)
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act. This classification allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, and the Company has elected to use adoption dates applicable to private companies. The Company will lose its EGC status on December 31, 2021 and qualify as a large accelerated filer based on its market capitalization as of June 30, 2021, according to Rule 12b-2 of the Securities Exchange Act of 1934, as amended. As a result, the Company will adopt all accounting pronouncements currently deferred under the EGC election according to public company standards beginning with its Annual Report on Form 10-K for the year ending December 31, 2021 (“2021 Annual Report”), including interim period disclosures within that filing. The adoption dates for the new accounting pronouncements disclosed below have been presented accordingly. In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment . ASU 2017-04 simplifies the accounting for goodwill impairments by eliminating the requirement to compare the implied fair value of goodwill with its carrying amount as part of step two of the goodwill impairment test referenced in ASC 350, Intangibles – Goodwill and Other . As a result, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. However, the impairment loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for smaller reporting companies for annual reporting periods beginning after December 15, 2022, including any interim impairment tests within those annual periods, with early application permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. In January 2021, the Company elected to early adopt ASU 2017-04, and the adoption had no impact on the consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement , which amends ASC 820, Fair Value Measurement . This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2019, with early adoption permitted for removed disclosures and delayed adoption until fiscal year 2020 permitted for the new disclosures. The Company adopted this disclosure requirement for the year ended December 31, 2020 and disclosures are presented accordingly. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which requires lessees to recognize leases on their balance sheets and disclose key information about leasing arrangements. The ASU establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition on the income statement. In July 2018, the FASB approved an amendment to the new guidance that allows companies the option of using the effective date of the new standard as the initial application (at the beginning of the period in which it is adopted, rather than at the beginning of the earliest comparative period) and to recognize the effects of applying the new ASU as a cumulative effect adjustment to the opening balance sheet or retained earnings. ASU 2016-12 is effective for annual periods beginning after December 15, 2018 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual and interim periods beginning after December 15, 2021, with early adoption permitted. The Company plans to adopt Topic 842 for the 2021 Annual Report. The Company is still evaluating the adoption approach as well as the impact of adopting this ASU, and expects to report increased assets and liabilities as a result of recording ROU assets and lease liabilities. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments to require the measurement of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance also amended the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on such debt security is a credit loss. The standard is effective for nonpublic companies for annual and interim periods beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company does not expect the impact of the adoption of this ASU to be material. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which is intended to improve consistency and simplify several areas of existing guidance. ASU 2019-12 removes certain exceptions to the general principles related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company is still evaluating the impact of the adoption of this ASU and does not expect the impact to be material. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The guidance includes amendments to improve the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to the financial statements is codified in the disclosure section of the codification and to clarify guidance so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 for public entities, including interim periods within those fiscal years. The standard is effective for nonpublic companies for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company plans to adopt the update for the 2021 Annual Report. The Company does not expect the impact of the adoption of this ASU to be material.
Fair Value Measurements	The fair value measurements of the identified intangible assets were based primarily on significant unobservable inputs and thus represent a Level 3 measurement as defined in ASC 820. The fair values of trade name and developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, customer churn rate, technology life, royalty rate, and discount rate. The fair value of customer relationships was determined using the multi-period excess earnings method which involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	Total cash, cash equivalents, and restricted cash are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash and cash equivalents $ 64,772 $ 27,344 Restricted cash 856 1,006 Total cash, cash equivalents, and restricted cash $ 65,628 $ 28,350
Restrictions on Cash and Cash Equivalents	Total cash, cash equivalents, and restricted cash are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash and cash equivalents $ 64,772 $ 27,344 Restricted cash 856 1,006 Total cash, cash equivalents, and restricted cash $ 65,628 $ 28,350
Disaggregation of Revenue	Revenue consists of the following (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Online $ 72,032 $ 38,829 $ 180,858 $ 100,637 Wholesale 2,141 2,495 6,321 6,654 Total revenue $ 74,173 $ 41,324 $ 187,179 $ 107,291

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 1,470 Other intangible assets 570 Goodwill 2,739 Other net assets 24 Net assets acquired $ 4,803 The following table summarizes the preliminary acquisition date fair values of assets acquired and liabilities assumed (in thousands): Trade name $ 22,700 Other intangible assets 3,140 Goodwill 108,142 Other net liabilities (2,346) Net assets acquired $ 131,636

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Short-term investments as of September 30, 2021, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 149,606 $ 1 $ (12) $ 149,595 Government bonds 15,499 — — 15,499 Asset-backed bonds 22,559 1 (1) 22,559 Total short-term investments $ 187,664 $ 2 $ (13) $ 187,653 Short-term investments as of December 31, 2020, consist of the following (in thousands): Adjusted Unrealized Unrealized Fair Corporate bonds $ 55,224 $ 5 $ (2) $ 55,227 Government bonds 14,121 2 — 14,123 Asset-backed bonds 3,514 — — 3,514 Total short-term investments $ 72,859 $ 7 $ (2) $ 72,864

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in thousands): September 30, December 31, Finished goods $ 9,230 $ 2,856 Raw materials 1,628 687 Total inventory $ 10,858 $ 3,543

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Trade and other receivables, net $ 1,324 $ 1,147 Prepaid expenses 8,910 2,691 Other current assets 716 1,566 Total prepaid expenses and other current assets $ 10,950 $ 5,404

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): September 30, December 31, Marketing expenses $ 4,344 $ 1,122 Payroll costs 3,101 919 Professional services 866 1,241 Tax payables 755 651 Warrant exercise deposit liability — 664 Other accrued liabilities 2,140 387 Total accrued liabilities $ 11,206 $ 4,984

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 57,575 $ — $ — $ 57,575 Government bonds — 3,024 — 3,024 Short-term investments: Corporate bonds — 149,595 — 149,595 Government bonds — 15,499 — 15,499 Asset-backed bonds — 22,559 — 22,559 Restricted cash: Money market funds 856 — — 856 Total assets $ 58,431 $ 190,677 $ — $ 249,108 Liabilities Earn-out liabilities, current — — 23,205 23,205 Earn-out liabilities, long-term — — 11,200 11,200 Total liabilities $ — $ — $ 34,405 $ 34,405 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 12,163 $ — $ — $ 12,163 Government bonds — 12,693 — 12,693 Short-term investments: Corporate bonds — 55,227 — 55,227 Government bonds — 14,123 — 14,123 Asset-backed bonds — 3,514 — 3,514 Restricted cash: Money market funds 1,006 — — 1,006 Total assets $ 13,169 $ 85,557 $ — $ 98,726 Liabilities Warrant liabilities $ — $ — $ 906 $ 906 Total liabilities $ — $ — $ 906 $ 906
Schedule of Share-based Payment Award, Equity Instrument Other Than Options, Valuation Assumptions	The following assumptions were used for the valuation of the Private Placement Warrants on the settlement date: Expected term 0.16 Volatility 65.0 % Risk-free rate — % Dividend yield — % Expected term (in years) 5.00 Expected volatility 60.0 % Risk-free interest rate 0.5 % Expected dividend yield — %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The change in the fair value of warrant liabilities is as follows (in thousands): Balance at December 31, 2020 $ 906 Conversion of Series D preferred stock warrants to Class A common stock warrants (1,160) Private Placement Warrants and Public Warrants 51,814 Redeemed/exercised warrants (37,859) Change in fair value (13,701) Balance at September 30, 2021 $ — Balance at December 31, 2020 $ — HHL acquisition 1,208 Apostrophe acquisition 32,650 Change in fair value due to revaluation and service-based vesting 547 Balance at September 30, 2021 $ 34,405
Fair Value Measurement Inputs and Valuation Techniques	The following assumptions were used to determine the fair value: HHL Apostrophe Revenue risk-adjusted discount rate 9.1 % 4.9 % Revenue volatility 50.0 % 50.0 % Counterparty discount rate 5.0 % 5.0 %

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease commitments subsequent to September 30, 2021 are as follows (in thousands): 2021 $ 384 2022 1,559 2023 1,598 2024 1,638 2025 1,114 Total $ 6,293

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The grant date fair value of the Company’s stock options granted was estimated using the following weighted average assumptions for the nine months ended September 30, 2021: Expected term (in years) 5.93 Expected volatility 58.6 % Risk-free interest rate 0.9 % Expected dividend yield — %
Share-based Payment Arrangement, Option, Activity	Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2020 26,459 $ 1.16 8.50 $ 131,770 Recapitalization (14,474) 1.41 Outstanding at December 31, 2020 11,985 $ 2.57 8.50 $ 131,770 Granted 1,255 12.69 Exercised (including early exercised options vested during the period) (1,288) 0.73 Forfeited and expired (249) 4.31 Outstanding at September 30, 2021 11,703 3.80 8.09 52,937 Vested and expected to vest as of September 30, 2021 11,703 3.80 8.09 52,937 Exercisable as of September 30, 2021 10,346 2.83 7.92 52,108
Share-based Payment Arrangement, Option, Exercise Price Range	The options outstanding and exercisable as of September 30, 2021 (excluding CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life Shares Weighted Average Remaining Contractual Life $ 0.06 – 0.40 2,593 6.46 2,590 6.46 1.55 – 2.33 3,047 7.64 2,910 7.64 2.43 – 3.65 3,254 8.67 3,254 8.67 8.17 – 12.26 1,871 9.31 1,490 9.23 12.79 – 19.19 938 9.55 102 9.45 11,703 10,346
Schedule of Share-based Payment Award, Equity Instrument Other Than Options, Valuation Assumptions	The following assumptions were used for the valuation of the Private Placement Warrants on the settlement date: Expected term 0.16 Volatility 65.0 % Risk-free rate — % Dividend yield — % Expected term (in years) 5.00 Expected volatility 60.0 % Risk-free interest rate 0.5 % Expected dividend yield — %
Share-based Payment Arrangement, Restricted Stock Unit, Activity	RSU activity including RSUs outstanding prior to the Merger, earn-out RSUs, and Parent Warrant RSUs is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2020 3,480 $ 5.30 Recapitalization (1,904) 5.99 Unvested at December 31, 2020 1,576 11.29 Granted 4,540 12.09 Vested (1,385) 12.76 Forfeited and expired (211) 10.93 Unvested at September 30, 2021 4,520 $ 11.64
Share-based Payment Arrangement, Activity	Vendor warrant activity, excluding any right to receive Merger consideration, is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Average Exercise Price Weighted Average Contractual Term (in Years) Aggregate Intrinsic Value Outstanding at December 31, 2020 1,861 $ 0.79 7.01 $ 9,957 Recapitalization (1,018) 0.96 Outstanding at December 31, 2020 843 $ 1.75 7.01 $ 9,957 Exercised (381) 1.75 Outstanding at September 30, 2021 462 1.75 7.01 2,677 Vested and expected to vest as of September 30, 2021 462 1.75 7.01 2,677 Exercisable as of September 30, 2021 462 1.75 7.01 2,677
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Marketing $ 2,328 $ 261 $ 4,946 $ 919 Selling, general, and administrative 9,541 1,153 50,313 3,824 Total stock-based compensation expense $ 11,869 $ 1,414 $ 55,259 $ 4,743

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Temporary Equity	The following table is a summary of Hims’ redeemable convertible preferred stock as of December 31, 2020 (in thousands, except for share data): Series Shares Shares Aggregate Proceeds, Issue Price Series Seed 4,987,477 4,987,477 $ — $ — $ 0.0001 Series A 23,822,492 23,822,492 6,621 5,106 0.2780 Series A-1 5,742,012 5,742,012 753 740 0.1312 Series B 13,270,590 13,270,590 24,600 23,429 1.8538 Series B-1 9,807,952 9,807,952 20,000 14,965 2.0392 Series B-2 13,464,939 13,464,939 51,371 49,911 3.8152 Series C 14,850,340 14,760,594 113,072 92,590 7.6604 Series D 10,051,872 7,472,062 52,035 51,900 6.9639 Total 95,997,674 93,328,118 $ 268,452 $ 238,641

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Class A Class V Class A Class F Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (15,273) $ (668) $ (4,727) $ (1,144) $ (73,219) $ (3,279) $ (10,355) $ (2,530) Denominator: Weighted average shares outstanding, basic and diluted 191,661,138 8,377,623 28,673,246 6,941,352 174,072,957 7,794,565 28,404,620 6,941,352 Basic and diluted net loss per share $ (0.08) $ (0.08) $ (0.16) $ (0.16) $ (0.42) $ (0.42) $ (0.36) $ (0.36)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table discloses securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 16,345,627 1,168,952 16,570,671 Common stock issued for early exercise of stock options 130,925 191,337 235,766 216,401 Redeemable convertible preferred stock — 92,318,613 6,495,364 89,293,938 Stock options 16,608,921 15,028,510 16,494,336 10,291,433 RSUs 4,447,842 — 3,972,999 — Warrants to purchase Class A common stock 2,773,408 1,793,993 6,199,099 1,861,315 Warrants to purchase redeemable convertible preferred stock — 704,633 — 1,158,407 Common stock issued subject to vesting 2,754,756 — 961,130 —

Organization (Details)

Organization (Details)	Jan. 20, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recapitalization exchange ratio	0.4530

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 64,772	$ 27,344
Restricted cash	856	1,006
Total cash, cash equivalents, and restricted cash	$ 65,628	$ 28,350	$ 37,406	$ 22,797

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 74,173	$ 41,324	$ 187,179	$ 107,291
Online
Disaggregation of Revenue [Line Items]
Total revenue	72,032	38,829	180,858	100,637
Wholesale
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,141	$ 2,495	$ 6,321	$ 6,654

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years

Recapitalization (Details)

Recapitalization (Details) $ / shares in Units, $ in Thousands	Jan. 20, 2021$ / sharesshares	Jan. 20, 2021USD ($)$ / sharesshares	Jan. 20, 2021$ / sharesshares	Jan. 20, 2021$ / sharesshares	Jan. 20, 2021d$ / sharesshares	Jan. 20, 2021day$ / sharesshares	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Jan. 19, 2021$ / shares	Dec. 31, 2020$ / shares
Reverse Recapitalization [Line Items]
Reverse recapitalization, percentage of voting interests acquired	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Proceeds from issuance of common stock, recapitalization | $		$ 197,700					$ 197,686	$ 0
Reverse recapitalization, deferred transaction costs | $		$ 18,700
Recapitalization exchange ratio	0.4530	0.4530	0.4530	0.4530	0.4530	0.4530
Reverse recapitalization, contingent consideration, equity (in shares) | shares				16,000,000
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15	$ 15	$ 15	$ 15	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50	17.50	17.50	17.50	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20	$ 20	$ 20	$ 20	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days					10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading day period | d					20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Chief Executive Officer
Reverse Recapitalization [Line Items]
Recapitalization exchange ratio	0.4530	0.4530	0.4530	0.4530	0.4530	0.4530
Common Class A
Reverse Recapitalization [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	0.0028	0.0028	0.0028	0.0028	0.0028	0.0028
Parent Warrant Restricted Stock Units | Hims' Option And RSU Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	35,000	35,000	35,000	35,000	35,000	35,000
Common Class A and V | Common Stock
Reverse Recapitalization [Line Items]
Recapitalization, contingent consideration, equity, exchange ratio			0.0443
Common Class A
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001
Common Class A | Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common Class A | Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)									$ 0.000001
Common Class A | Parent Warrants
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	888,143	888,143	888,143	888,143	888,143	888,143
Common Class A | Parent Warrants | Hims' Stockholders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	888,143	888,143	888,143	888,143	888,143	888,143
Common Class A | Parent Warrants | Hims' Warrant Holders
Reverse Recapitalization [Line Items]
Class of warrant or right, outstanding (in shares) | shares	3,443	3,443	3,443	3,443	3,443	3,443
Common Class V
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)							$ 0.0001
Common Class V | Chief Executive Officer
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common Class V | Hims, Inc.
Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share)									$ 0.000001
PIPE Investment
Reverse Recapitalization [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares				7,500,000
Sale of stock, price per share (in dollars per share)	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10
Sale of stock, consideration received on transaction | $		$ 75,000

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details)	Jun. 11, 2021USD ($)shares	Jul. 31, 2021USD ($)shares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)acquisition	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Jul. 02, 2021USD ($)	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Number of acquisitions | acquisition					2
Goodwill			$ 110,881,000		$ 110,881,000		$ 110,881,000		$ 0
Honest Health Limited
Business Acquisition [Line Items]
Business combination, consideration	$ 4,800,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) | shares	624,880
Business combination, consideration transferred, equity interests issued and issuable	$ 1,900,000
Business combination, consideration transferred, liabilities incurred	1,200,000
Potential earnout payable	10,000,000
Business combination, acquisition related costs	1,800,000
Goodwill	2,739,000
Business acquisition, goodwill, expected tax deductible amount	$ 0
Honest Health Limited | Minimum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, useful life	2 years
Honest Health Limited | Maximum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, useful life	5 years
Apostrophe
Business Acquisition [Line Items]
Business combination, consideration		$ 131,600,000
Business acquisition, equity interest issued or issuable, number of shares (in shares) | shares		8,074,935
Business combination, consideration transferred, equity interests issued and issuable		$ 50,700,000
Business combination, consideration transferred, liabilities incurred		32,700,000
Potential earnout payable		50,000,000
Business combination, acquisition related costs		4,900,000
Goodwill		108,100,000						$ 108,142,000
Business acquisition, goodwill, expected tax deductible amount		0
Cash consideration		$ 48,200,000
Amortization expense related to intangible assets			900,000		900,000
Business combination, pro forma information, revenue of acquiree since acquisition date, actual							$ 5,000,000
Business acquisition, pro forma revenue			$ 5,000,000	$ 3,000,000	$ 15,000,000	$ 9,000,000
Apostrophe | Minimum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, useful life		2 years
Apostrophe | Maximum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets, useful life		10 years

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jul. 31, 2021	Jul. 02, 2021	Jun. 11, 2021	Dec. 31, 2020
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill	$ 110,881				$ 0
Honest Health Limited
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name				$ 1,470
Other intangible assets				570
Goodwill				2,739
Other net assets (liabilities)				24
Net assets acquired				$ 4,803
Apostrophe
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Trade name			$ 22,700
Other intangible assets			3,140
Goodwill		$ 108,100	108,142
Other net assets (liabilities)			(2,346)
Net assets acquired			$ 131,636

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Adjusted Cost	$ 187,664	$ 72,859
Unrealized Gains	2	7
Unrealized Losses	(13)	(2)
Fair Value	187,653	72,864
Corporate bonds
Marketable Securities [Line Items]
Adjusted Cost	149,606	55,224
Unrealized Gains	1	5
Unrealized Losses	(12)	(2)
Fair Value	149,595	55,227
Government bonds
Marketable Securities [Line Items]
Adjusted Cost	15,499	14,121
Unrealized Gains	0	2
Unrealized Losses	0	0
Fair Value	15,499	14,123
Asset-backed bonds
Marketable Securities [Line Items]
Adjusted Cost	22,559	3,514
Unrealized Gains	1	0
Unrealized Losses	(1)	0
Fair Value	$ 22,559	$ 3,514

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 9,230	$ 2,856
Raw materials	1,628	687
Total inventory	$ 10,858	$ 3,543

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Trade and other receivables, net	$ 1,324	$ 1,147
Prepaid expenses	8,910	2,691
Other current assets	716	1,566
Total prepaid expenses and other current assets	$ 10,950	$ 5,404

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Marketing expenses	$ 4,344	$ 1,122
Payroll costs	3,101	919
Professional services	866	1,241
Tax payables	755	651
Warrant exercise deposit liability	0	664
Other accrued liabilities	2,140	387
Total accrued liabilities	$ 11,206	$ 4,984

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Variable Interest Entity [Line Items]
Current assets	$ 274,233						$ 274,233		$ 113,084
Assets	420,069						420,069		118,697
Current liabilities	52,498						52,498		15,228
Liabilities	64,916						64,916		15,609
Net loss	(15,941)	$ (9,153)	$ (51,404)	$ (5,871)	$ (981)	$ (6,033)	$ (76,498)	$ (12,885)
Affiliated Medical Groups
Variable Interest Entity [Line Items]
Percentage owned by licensed physicians							100.00%
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Current assets	1,500						$ 1,500		1,500
Assets	1,400						1,400		1,400
Current liabilities	1,400						1,400		800
Liabilities	1,800						1,800		$ 1,200
Net loss	(700)			1,400			(3,600)	(700)
Variable Interest Entity, Primary Beneficiary | Consolidation, Eliminations
Variable Interest Entity [Line Items]
Payments for services	$ 7,200			$ 5,600			$ 14,800	$ 9,200

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out liabilities, current	$ 23,205	$ 0
Earn-out liabilities, long-term	11,200	0
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	249,108	98,726
Earn-out liabilities, current	23,205
Earn-out liabilities, long-term	11,200
Warrant liabilities		906
Total liabilities	34,405	906
Fair Value, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	149,595	55,227
Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	15,499	14,123
Fair Value, Recurring | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	22,559	3,514
Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	57,575	12,163
Restricted cash	856	1,006
Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	3,024	12,693
Level 1 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	58,431	13,169
Earn-out liabilities, current	0
Earn-out liabilities, long-term	0
Warrant liabilities		0
Total liabilities	0	0
Level 1 | Fair Value, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 1 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 1 | Fair Value, Recurring | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 1 | Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	57,575	12,163
Restricted cash	856	1,006
Level 1 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Level 2 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	190,677	85,557
Earn-out liabilities, current	0
Earn-out liabilities, long-term	0
Warrant liabilities		0
Total liabilities	0	0
Level 2 | Fair Value, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	149,595	55,227
Level 2 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	15,499	14,123
Level 2 | Fair Value, Recurring | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	22,559	3,514
Level 2 | Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Level 2 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	3,024	12,693
Level 3 | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Earn-out liabilities, current	23,205
Earn-out liabilities, long-term	11,200
Warrant liabilities		906
Total liabilities	34,405	906
Level 3 | Fair Value, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 | Fair Value, Recurring | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 | Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Level 3 | Fair Value, Recurring | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assumptions of Private Placement Warrants (Details) - Private Placement Warrants	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	1 month 28 days
Expected volatility	65.00%
Risk-free interest rate	0.00%
Expected dividend yield	0.00%

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of Warrant Liabilities (Details) - Warrant liabilities $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2020	$ 906
Conversion of Series D preferred stock warrants to Class A common stock warrants	(1,160)
Private Placement Warrants and Public Warrants	51,814
Redeemed/exercised warrants	(37,859)
Change in fair value	(13,701)
Balance at September 30, 2021	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Jul. 31, 2021	Jun. 11, 2021
Honest Health Limited | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability		$ 0
Honest Health Limited | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability		$ 3,300,000
Apostrophe | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability	$ 0
Apostrophe | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability	$ 49,400,000

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Assumptions (Details) - Level 3 - Valuation, Income Approach	Sep. 30, 2021
Revenue risk-adjusted discount rate | Honest Health Limited
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.091
Revenue risk-adjusted discount rate | Apostrophe
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.049
Revenue volatility | Honest Health Limited
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.500
Revenue volatility | Apostrophe
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.500
Counterparty discount rate | Honest Health Limited
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.050
Counterparty discount rate | Apostrophe
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.050

Fair Value Measurements - Cha_2

Fair Value Measurements - Change in the Fair Value of Earn-out Liabilities (Details) - Earn-out Liability $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2020	$ 0
Change in fair value due to revaluation and service-based vesting	547
Balance at September 30, 2021	34,405
Honest Health Limited
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition	1,208
Apostrophe
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition	$ 32,650

Borrowing Arrangements (Details

Borrowing Arrangements (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 12, 2020	Feb. 29, 2020	Nov. 30, 2019	Nov. 27, 2019
Line of Credit Facility [Line Items]
Restricted cash	$ 856,000		$ 1,006,000
Series C Preferred Stock Warrants
Line of Credit Facility [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)					89,747	1,341,865	89,747	89,747
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 7.67			$ 7.67
Series D Preferred Stock Warrants
Line of Credit Facility [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)					98,723
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 6.96
Business Credit Card | Line of Credit
Line of Credit Facility [Line Items]
Debt instrument, covenant, required collateral amount		$ 200,000
Capital Agreement, 2019 | Notes Payable, Other Payables
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity								$ 50,000,000
Debt, long-term and short-term, combined amount			$ 0
Capital Agreement, 2019, Tranche One | Notes Payable, Other Payables
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity								25,000,000
Capital Agreement, 2019, Tranche Two | Notes Payable, Other Payables
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity								25,000,000
Letter of Credit | Line of Credit
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity				$ 3,500,000				$ 2,000,000
Proceeds from issuance of debt	800,000
Debt instrument, covenant, required collateral amount	800,000
Restricted cash	$ 800,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Details (Details) $ in Thousands	Jan. 20, 2021	Jan. 31, 2020USD ($)ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Other Commitments [Line Items]
Operating leases, rent expense			$ 300	$ 300	$ 1,100	$ 1,700
Operating lease, term of contract		63 months
Operating leases, future minimum payments due		$ 7,900	6,293		6,293
Lessee, operating lease, period for payments net of rent abatement	3 months
Rent expense, annual escalation, percent		2.50%
Operating lease, renewal term		5 years
Purchase obligation			$ 2,100		$ 2,100
New Albany, Ohio
Other Commitments [Line Items]
Area of real estate property | ft²		302,880

Commitment and Contingencies -

Commitment and Contingencies - Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
2021	$ 384
2022	1,559
2023	1,598
2024	1,638
2025	1,114
Total	$ 6,293	$ 7,900

Stock-Based Compensation - 2017

Stock-Based Compensation - 2017 Stock Plan and 2020 Equity Incentive Plan (Details) - shares	1 Months Ended	9 Months Ended
	Jan. 31, 2021	Sep. 30, 2021
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)		10 years
2020 Equity Incentive Plan and 2017 Stock Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)		5 years
2020 Equity Incentive Plan and 2017 Stock Plan | Minimum | Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent		100.00%
2020 Equity Incentive Plan and 2017 Stock Plan | Minimum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent		110.00%
Stockholders equity ownership, percent		10.00%
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	21,000,000	21,335,577
Percentage increase in authorized shares of common stock	5.00%
Number of shares available for grant (in shares)		16,418,493
Stock Plan, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	19,000,000
Number of authorized shares transferred between plans (in shares)	335,577
Number of shares available for grant (in shares)		0

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Narrative (Details) $ / shares in Units, $ in Thousands	Jun. 17, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Feb. 28, 2021shares	Jan. 20, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense		$ 11,869		$ 1,414	$ 55,259	$ 4,743
Recapitalization exchange ratio								0.4530
Weighted average grant date fair value (in dollars per share) | $ / shares					$ 6.81
Intrinsic value of exercises during period					$ 9,200
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value	$ 16,600
Exercisable at the end of the period (in shares) | shares							3,246,139
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount		$ 3,500			$ 3,500
Options outstanding (in shares) | shares		1,623,070			1,623,070
Recapitalization exchange ratio								0.4530
Chief Executive Officer | June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares	3,246,139
Awards granted (in dollars per share) | $ / shares	$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares	$ 22.99
Chief Executive Officer | June 17, 2020 Grant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares	1,623,070
Awards granted (in dollars per share) | $ / shares	$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares	$ 38.31
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount		$ 21,300			$ 21,300
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					4 years
Expiration period (in years)					10 years
Stock options | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition					2 years 6 months 14 days
Stock options | Chief Executive Officer | June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense			$ 11,300
Stock options | New Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					4 years
Award vesting rights, monthly percentage					2.083%
Stock options | New Employee | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					1 year
Awards vesting rights, percentage					25.00%
Stock options | Current Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					4 years
Award vesting rights, monthly percentage					2.083%
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition					3 years 18 days

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted Average Fair Value Assumptions (Details) - Stock options	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 11 months 4 days
Expected volatility	58.60%
Risk-free interest rate	0.90%
Expected dividend yield	0.00%

Stock-Based Compensation - Opti

Stock-Based Compensation - Option Activity (Details) - Employee, excluding CEO $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Shares
Beginning balance (in shares) | shares	11,985
Granted (in shares) | shares	1,255
Exercised (in shares) | shares	(1,288)
Forfeited and expired (in shares) | shares	(249)
Ending balance (in shares) | shares	11,703	11,985
Vested and expected to vest at the end of the period (in shares) | shares	11,703
Exercisable at the end of the period (in shares) | shares	10,346
Weighted Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 2.57
Granted (in dollars per share) | $ / shares	12.69
Exercised (in dollars per share) | $ / shares	0.73
Forfeited and expired (in dollars per share) | $ / shares	4.31
Ending balance (in dollars per share) | $ / shares	3.80	$ 2.57
Vested and expected to vest at the end of the period (in dollars per share) | $ / shares	3.80
Exercisable at the end of the period (in dollars per share) | $ / shares	$ 2.83
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)	8 years 1 month 2 days	8 years 6 months
Vested and expected to vested at the end of the period (in years)	8 years 1 month 2 days
Exercisable at the end of the period (in years)	7 years 11 months 1 day
Aggregate Intrinsic Value
Outstanding balance | $	$ 52,937	$ 131,770
Vested and expected to vest at the end of the period | $	52,937
Exercisable at the end of the period | $	$ 52,108
Previously Reported
Shares
Beginning balance (in shares) | shares	26,459
Ending balance (in shares) | shares		26,459
Weighted Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 1.16
Ending balance (in dollars per share) | $ / shares		$ 1.16
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares) | shares	14,474
Ending balance (in shares) | shares		14,474
Weighted Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 1.41
Ending balance (in dollars per share) | $ / shares		$ 1.41

Stock-Based Compensation - Exer

Stock-Based Compensation - Exercise Price Range of Options Outstanding and Exercisable (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Options Outstanding
Shares (in shares)	11,703
Options Exercisable
Shares (in shares)	10,346
Exercise Price Range $0.06 to $0.40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 0.06
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 0.40
Options Outstanding
Shares (in shares)	2,593
Weighted Average Remaining Contractual Life  (in Years)	6 years 5 months 15 days
Options Exercisable
Shares (in shares)	2,590
Weighted Average Remaining Contractual Life  (in Years)	6 years 5 months 15 days
Exercise Price Range $1.55 to $2.33
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 1.55
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 2.33
Options Outstanding
Shares (in shares)	3,047
Weighted Average Remaining Contractual Life  (in Years)	7 years 7 months 20 days
Options Exercisable
Shares (in shares)	2,910
Weighted Average Remaining Contractual Life  (in Years)	7 years 7 months 20 days
Exercise Price Range $2.43 to $3.65
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 2.43
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 3.65
Options Outstanding
Shares (in shares)	3,254
Weighted Average Remaining Contractual Life  (in Years)	8 years 8 months 1 day
Options Exercisable
Shares (in shares)	3,254
Weighted Average Remaining Contractual Life  (in Years)	8 years 8 months 1 day
Exercise Price Range $8.17 to $12.26
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 8.17
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 12.26
Options Outstanding
Shares (in shares)	1,871
Weighted Average Remaining Contractual Life  (in Years)	9 years 3 months 21 days
Options Exercisable
Shares (in shares)	1,490
Weighted Average Remaining Contractual Life  (in Years)	9 years 2 months 23 days
Exercise Price Range $12.79 to $19.19
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 12.79
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 19.19
Options Outstanding
Shares (in shares)	938
Weighted Average Remaining Contractual Life  (in Years)	9 years 6 months 18 days
Options Exercisable
Shares (in shares)	102
Weighted Average Remaining Contractual Life  (in Years)	9 years 5 months 12 days

Stock-Based Compensation - RSUs

Stock-Based Compensation - RSUs Narrative (Details) $ / shares in Units, $ in Millions	Jan. 20, 2021$ / shares	Jan. 20, 2021d$ / shares	Jan. 20, 2021day$ / shares	Jan. 31, 2021shares	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530	0.4530	0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share) | $ / shares	$ 15	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share) | $ / shares	17.50	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share) | $ / shares	$ 20	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days		10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | day			20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530	0.4530	0.4530
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					4 years
Share price (in dollars per share) | $ / shares					$ 16.38
Vested (in shares)					1,385,000
Granted (in shares)					4,540,000	45,297
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $					$ 42.5
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition					2 years 11 months 15 days
RSUs | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)					1 year
Awards vesting rights, percentage					25.00%
Earn Out Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)					317,539
Earn Out Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)					476,308
Earn Out Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				4,431
Parent Warrant Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)					6,319
Parent Warrant Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)					9,478
Parent Warrant Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				88

Stock-Based Compensation - RS_2

Stock-Based Compensation - RSUs Weighted Average Fair Value Assumptions (Details) - RSUs	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years
Expected volatility	60.00%
Risk-free interest rate	0.50%
Expected dividend yield	0.00%

Stock-Based Compensation - RS_3

Stock-Based Compensation - RSUs Activity (Details) - RSUs - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	1,576,000
Granted (in shares)	4,540,000	45,297
Vested (in shares)	(1,385,000)
Forfeited and expired (in shares)	(211,000)
Ending balance (in shares)	4,520,000	1,576,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 11.29
Granted (in dollars per share)	12.09
Vested (in dollars per share)	12.76
Forfeited and expired (in dollars per share)	10.93
Ending balance (in dollars per share)	$ 11.64	$ 11.29
Previously Reported
Shares
Beginning balance (in shares)	3,480,000
Ending balance (in shares)		3,480,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 5.30
Ending balance (in dollars per share)		$ 5.30
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares)	1,904,000
Ending balance (in shares)		1,904,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 5.99
Ending balance (in dollars per share)		$ 5.99

Stock-Based Compensation - Vend

Stock-Based Compensation - Vendor Warrants Narrative (Details)	Jan. 20, 2021$ / shares	Jan. 20, 2021d$ / shares	Jan. 20, 2021day$ / shares	Sep. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530	0.4530	0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days		10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | day			20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Earn-Out Consideration
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares) | shares				45,225

Stock-Based Compensation - Ve_2

Stock-Based Compensation - Vendor Warrant Activity (Details) - Vendor Warrants - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	462	843
Exercised (in shares)	(381)
Ending balance (in shares)	462	843
Vested and expected to vest at the end of period (in shares)	462
Exercisable at the end of period (in shares)	462
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 1.75
Exercised (in dollars per share)	1.75
Ending balance (in dollars per share)	1.75	$ 1.75
Vested and expected to vest at the end of period (in dollars per share)	1.75
Exercisable at the end of period (in dollars per share)	$ 1.75
Weighted Average Contractual Term (in Years)
Outstanding (in years)	7 years 3 days	7 years 3 days
Vested and expected to vest at the end of period (in years)	7 years 3 days
Exercisable at the end of period (in years)	7 years 3 days
Aggregate Intrinsic Value
Outstanding	$ 2,677	$ 9,957
Vested and expected to vest and the end of period	2,677
Exercisable at the end of period	$ 2,677
Previously Reported
Shares
Beginning balance (in shares)		1,861
Ending balance (in shares)		1,861
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.79
Ending balance (in dollars per share)		$ 0.79
Weighted Average Contractual Term (in Years)
Outstanding (in years)		7 years 3 days
Aggregate Intrinsic Value
Outstanding		$ 9,957
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares)		1,018
Ending balance (in shares)		1,018
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.96
Ending balance (in dollars per share)		$ 0.96

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Subject to Vesting and Earn-out Share Liability (Details) - Restricted Stock - USD ($) $ in Millions	Jun. 11, 2021	Jul. 31, 2021	Sep. 30, 2021	Jun. 30, 2021
Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 5.5
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 6 months 29 days
Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 22.2
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 9 months 3 days
Employee | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Employee | Honest Health Limited | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	447,553
Aggregate grant date fair value				$ 5.5
Employee | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Employee | Apostrophe | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		2,332,557
Aggregate grant date fair value		$ 24.2
Employee | Share-based Payment Arrangement, Tranche One | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	1 year
Awards vesting rights, percentage	25.00%
Employee | Share-based Payment Arrangement, Tranche One | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		6 months
Awards vesting rights, percentage		17.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Employees and Nonemployees (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 11,869,000	$ 1,414,000	$ 55,259,000	$ 4,743,000
Share-based payment arrangement, amount capitalized	200,000	0	500,000	0
Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,328,000	261,000	4,946,000	919,000
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 9,541,000	$ 1,153,000	$ 50,313,000	$ 3,824,000

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($)	5 Months Ended	12 Months Ended
	Jul. 31, 2020	Dec. 31, 2020	Sep. 30, 2021
Temporary Equity [Line Items]
Shares Authorized (in shares)		95,997,674	275,000,000
Shares Issued (in shares)		93,328,118	0
Shares Outstanding (in shares)		93,328,118	0
Aggregate Liquidation Value		$ 268,452,000	$ 0
Proceeds, Net of Issuance Costs		$ 238,641,000
Series Seed
Temporary Equity [Line Items]
Shares Authorized (in shares)		4,987,477
Shares Issued (in shares)		4,987,477
Shares Outstanding (in shares)		4,987,477
Aggregate Liquidation Value		$ 0
Proceeds, Net of Issuance Costs		$ 0
Issue Price per Share (in dollars per share)		$ 0.0001
Series A
Temporary Equity [Line Items]
Shares Authorized (in shares)		23,822,492
Shares Issued (in shares)		23,822,492
Shares Outstanding (in shares)		23,822,492
Aggregate Liquidation Value		$ 6,621,000
Proceeds, Net of Issuance Costs		$ 5,106,000
Issue Price per Share (in dollars per share)		$ 0.2780
Series A-1
Temporary Equity [Line Items]
Shares Authorized (in shares)		5,742,012
Shares Issued (in shares)		5,742,012
Shares Outstanding (in shares)		5,742,012
Aggregate Liquidation Value		$ 753,000
Proceeds, Net of Issuance Costs		$ 740,000
Issue Price per Share (in dollars per share)		$ 0.1312
Series B
Temporary Equity [Line Items]
Shares Authorized (in shares)		13,270,590
Shares Issued (in shares)		13,270,590
Shares Outstanding (in shares)		13,270,590
Aggregate Liquidation Value		$ 24,600,000
Proceeds, Net of Issuance Costs		$ 23,429,000
Issue Price per Share (in dollars per share)		$ 1.8538
Series B-1
Temporary Equity [Line Items]
Shares Authorized (in shares)		9,807,952
Shares Issued (in shares)		9,807,952
Shares Outstanding (in shares)		9,807,952
Aggregate Liquidation Value		$ 20,000,000
Proceeds, Net of Issuance Costs		$ 14,965,000
Issue Price per Share (in dollars per share)		$ 2.0392
Series B-2
Temporary Equity [Line Items]
Shares Authorized (in shares)		13,464,939
Shares Issued (in shares)		13,464,939
Shares Outstanding (in shares)		13,464,939
Aggregate Liquidation Value		$ 51,371,000
Proceeds, Net of Issuance Costs		$ 49,911,000
Issue Price per Share (in dollars per share)		$ 3.8152
Series C
Temporary Equity [Line Items]
Shares Authorized (in shares)		14,850,340
Shares Issued (in shares)		14,760,594
Shares Outstanding (in shares)		14,760,594
Aggregate Liquidation Value		$ 113,072,000
Proceeds, Net of Issuance Costs		$ 92,590,000
Issue Price per Share (in dollars per share)		$ 7.6604
Series D
Temporary Equity [Line Items]
Shares Authorized (in shares)		10,051,872
Shares Issued (in shares)	7,472,062	7,472,062
Shares Outstanding (in shares)		7,472,062
Aggregate Liquidation Value		$ 52,035,000
Proceeds, Net of Issuance Costs	$ 51,900,000	$ 51,900,000
Issue Price per Share (in dollars per share)		$ 6.9639

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	5 Months Ended	12 Months Ended
	Feb. 29, 2020USD ($)shares	Jul. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2021shares	Jan. 20, 2021	Mar. 12, 2020$ / sharesshares	Mar. 01, 2020USD ($)	Nov. 30, 2019shares	Nov. 27, 2019shares
Temporary Equity [Line Items]
Shares Issued (in shares) | shares			93,328,118	0
Proceeds from issuance of temporary equity | $			$ 238,641
Recapitalization exchange conversion basis					1
Recapitalization exchange ratio					0.4530
Series C Preferred Stock Warrants
Temporary Equity [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares) | shares	1,341,865					89,747		89,747	89,747
Warrants and rights outstanding | $	$ 10,000
Series D Preferred Stock Warrants
Temporary Equity [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares) | shares						98,723
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares						$ 6.96
Series D
Temporary Equity [Line Items]
Shares Issued (in shares) | shares		7,472,062	7,472,062
Proceeds from issuance of temporary equity | $		$ 51,900	$ 51,900
Series C Preferred Stock
Temporary Equity [Line Items]
Shares Issued (in shares) | shares			14,760,594
Proceeds from issuance of temporary equity | $			$ 92,590
Warrants and rights outstanding | $							$ 11,300
Conversion of convertible securities (in shares) | shares	1,341,865
Proceeds from conversion of convertible securities | $	$ 100

Common Stock - Additional Infor

Common Stock - Additional Information (Details) $ in Thousands	Jan. 20, 2021USD ($)shares	May 31, 2020USD ($)shares	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)shares	Jan. 19, 2021common_stock_class
Class of Stock [Line Items]
Number of classes of common stock | common_stock_class							2
Payments for repurchase of common stock				$ 22,027	$ 0
Pre-closing stock repurchase, net of exercise of vested options			$ 21,902
Repurchase of Stock | Former Executive Officer
Class of Stock [Line Items]
Notes receivable, amount of principal payment canceled		$ 900
Common Class A
Class of Stock [Line Items]
Pre-closing stock repurchase, net of exercise of vested options (in shares) | shares	183,548	509,602				85,594
Payments for repurchase of common stock	$ 22,000					$ 100
Stock repurchased and retired during period (in shares) | shares	2,207,580
Pre-closing stock repurchase, net of exercise of vested options	$ 1,800

Common Stock - Merger Transacti

Common Stock - Merger Transaction (Details)	Jan. 20, 2021$ / sharesshares	Sep. 30, 2021$ / shares	Jan. 19, 2021$ / shares	Dec. 31, 2020$ / shares
Class of Stock [Line Items]
Recapitalization exchange ratio	0.4530
Common Class A
Class of Stock [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	0.0028
Chief Executive Officer
Class of Stock [Line Items]
Recapitalization exchange ratio	0.4530
Common Class A and V | Common Stock
Class of Stock [Line Items]
Recapitalization, contingent consideration, equity, exchange ratio	0.0443
Common Class A
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Common Class A | Chief Executive Officer
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	0.0001
Common Class A | Hims, Inc.
Class of Stock [Line Items]
Common stock, par value (in dollars per share)			$ 0.000001
Common Class V
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001
Common Class V | Chief Executive Officer
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class V | Hims, Inc.
Class of Stock [Line Items]
Common stock, par value (in dollars per share)			$ 0.000001

Common Stock - Settlement of No

Common Stock - Settlement of Nonrecourse Related-Party Promissory Notes (Details) - Common Class A - Common Stock $ in Millions	Jan. 20, 2021USD ($)shares
Class of Stock [Line Items]
Proceeds from repayment of promissory notes associated with vested and unvested shares | $	$ 1.2
Common stock, forfeited (in shares) | shares	370,734

Common Stock - PIPE Investment

Common Stock - PIPE Investment (Details) - PIPE Investment $ / shares in Units, $ in Millions	Jan. 20, 2021USD ($)$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	7,500,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 10
Sale of stock, consideration received on transaction | $	$ 75

Common Stock - Prior to Merger

Common Stock - Prior to Merger (Details) - Common Class A - $ / shares	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Conversion of convertible securities (in shares)		1,958,615
Common Stock Warrants
Class of Warrant or Right [Line Items]
Conversion of convertible securities (in shares)			1,051,204
Common Stock Warrants | Minimum
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 0.06
Common Stock Warrants | Maximum
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 1.75
Vendor Warrants
Class of Warrant or Right [Line Items]
Conversion of convertible securities (in shares)	380,746
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.75

Common Stock - Subsequent to Me

Common Stock - Subsequent to Merger (Details)	Jan. 20, 2021$ / sharesshares	Jan. 20, 2021d$ / sharesshares	Jan. 20, 2021day$ / sharesshares	Feb. 28, 2021shares	Sep. 30, 2021shares	Jul. 09, 2021$ / shares
Class of Warrant or Right [Line Items]
Recapitalization exchange ratio	0.4530	0.4530	0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share) | $ / shares	$ 15	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share) | $ / shares	17.50	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share) | $ / shares	$ 20	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days		10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | day			20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
Common Class A
Class of Warrant or Right [Line Items]
Conversion of convertible securities (in shares) | shares					1,958,615
Private Placement Warrants | Common Class A
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	3,012,500	3,012,500	3,012,500	3,012,500
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 11.50	$ 11.50	$ 11.50
Conversion of convertible securities (in shares) | shares				1,474,145
Public Warrants
Class of Warrant or Right [Line Items]
Lock-up period expiration after merger	180 days
Public Warrants | Common Class A
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	6,708,333	6,708,333	6,708,333
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 11.50	$ 11.50	$ 11.50			$ 11.50
Parent Warrants | Common Class A
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	888,143	888,143	888,143

Common Stock - Public Warrant T

Common Stock - Public Warrant Terms (Details) - Common Class A	9 Months Ended
	Sep. 30, 2021day$ / shares	Aug. 09, 2021$ / shares
Public Warrants
Class of Warrant or Right [Line Items]
Exercisable period after closing date	30 days
Warrant expiration period	5 years
Period after warrants become exercisable for warrant redemption commencement	90 days
Class of warrant or right, redemption price per share (in dollars per share)		$ 0.10
Public Warrants, Warrant Redemption
Class of Warrant or Right [Line Items]
Class of warrant or right, redemption price per share (in dollars per share)	$ 0.10
Minimum period of prior notice for share redemption	30 days
Threshold trading days | day	10
Sale price redemption threshold (in dollars per share)	$ 10
Period after written notice of redemption	30 days

Common Stock - Warrant Redempti

Common Stock - Warrant Redemption (Details) - Common Class A	Jul. 09, 2021$ / shares	Sep. 30, 2021shares	Aug. 09, 2021$ / shares	Jan. 20, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion of preferred stock to common stock (in shares) | shares		1,958,615
Public Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, redemption price per share (in dollars per share)			$ 0.10
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 11.50			$ 11.50
Warrants exchange ratio	0.267

Common Stock - RSU Releases (De

Common Stock - RSU Releases (Details) - Common Class A - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, shares, share-based payment arrangement, after forfeiture (in shares)	248,659	1,385,811
Share-based payment arrangement, shares withheld for tax withholding obligation (in shares)	89,412	500,824

Common Stock - Shares Issued to

Common Stock - Shares Issued to Financial Advisor (Details)	Jan. 20, 2021shares
Financial Advisor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of earn-out shares to common stockholders (in shares)	250,000

Common Stock - Acquisitions (De

Common Stock - Acquisitions (Details) - Common Class A - shares	Jun. 11, 2021	Jul. 31, 2021
Honest Health Limited
Business Acquisition [Line Items]
Issuance of common stock for acquisition of business (in shares)	177,327
Shares issued in period (in shares)	447,553
Apostrophe
Business Acquisition [Line Items]
Issuance of common stock for acquisition of business (in shares)		5,742,378
Shares issued in period (in shares)		2,332,557

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 20, 2021	Sep. 23, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Redeemable Class A Common Stock
Related Party Transaction [Line Items]
Reclassifications of temporary to permanent equity						$ 4.5
Affiliated Entity
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party			$ 0.8	$ 1.4	$ 2.3	2.5
Affiliated Entity | Redeemable Common Stock Transaction
Related Party Transaction [Line Items]
Sale of stock, put right period		6 months
Affiliated Entity | Identity Verification Services
Related Party Transaction [Line Items]
Related party transaction, purchases from related party			$ 0.2		$ 0.5	$ 0.1
Affiliated Entity | Identity Verification Services | Maximum
Related Party Transaction [Line Items]
Related party transaction, purchases from related party				$ 0.1
Management | Nonrecourse Related-Party Promissory Notes
Related Party Transaction [Line Items]
Options outstanding (in shares)							16,345,627
Long-term debt, term							10 years
Long-term debt, term following initial public offering							6 months
Share-based compensation arrangement by share-based payment award, options, outstanding, value							$ 7.2
Proceeds from repayment of promissory notes associated with vested and unvested shares	$ 1.2
Forfeiture of related-party promissory notes (in shares)	370,734
Management | Nonrecourse Related-Party Promissory Notes | Maximum
Related Party Transaction [Line Items]
Related party transaction, rate							3.00%
Management | Nonrecourse Related-Party Promissory Notes | Minimum
Related Party Transaction [Line Items]
Related party transaction, rate							2.20%
Chief Executive Officer And Director | Sale of Stock from CEO and Member Of Board of Directors
Related Party Transaction [Line Items]
Sale of stock, number of shares issued in transaction (in shares)		737,058
Sale of stock, price per share (in dollars per share)		$ 6.11
Sale of stock, consideration received on transaction		$ 4.5
CEO And Director | Redeemable Common Stock Transaction
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party		$ 3

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dividends, common stock	$ 0	$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share (in shares)			0
Common Redeemable Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0
Common Class A Redeemable Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares subject to redemption (in shares)				220,579

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss attributable to common stockholders	$ (15,941)	$ (9,153)	$ (51,404)	$ (5,871)	$ (981)	$ (6,033)	$ (76,498)	$ (12,885)
Denominator:
Weighted average shares outstanding, basic (in shares)	200,038,761			35,614,598			181,867,522	35,345,972
Weighted average shares outstanding, diluted (in shares)	200,038,761			35,614,598			181,867,522	35,345,972
Basic net loss per share (in dollars per share)	$ (0.08)			$ (0.16)			$ (0.42)	$ (0.36)
Diluted net loss per share (in dollars per share)	$ (0.08)			$ (0.16)			$ (0.42)	$ (0.36)
Common Class A
Numerator:
Net loss attributable to common stockholders	$ (15,273)			$ (4,727)			$ (73,219)	$ (10,355)
Denominator:
Weighted average shares outstanding, basic (in shares)	191,661,138			28,673,246			174,072,957	28,404,620
Weighted average shares outstanding, diluted (in shares)	191,661,138			28,673,246			174,072,957	28,404,620
Basic net loss per share (in dollars per share)	$ (0.08)			$ (0.16)			$ (0.42)	$ (0.36)
Diluted net loss per share (in dollars per share)	$ (0.08)			$ (0.16)			$ (0.42)	$ (0.36)
Common Class V
Numerator:
Net loss attributable to common stockholders	$ (668)						$ (3,279)
Denominator:
Weighted average shares outstanding, basic (in shares)	8,377,623						7,794,565
Weighted average shares outstanding, diluted (in shares)	8,377,623						7,794,565
Basic net loss per share (in dollars per share)	$ (0.08)						$ (0.42)
Diluted net loss per share (in dollars per share)	$ (0.08)						$ (0.42)
Common Class F
Numerator:
Net loss attributable to common stockholders				$ (1,144)				$ (2,530)
Denominator:
Weighted average shares outstanding, basic (in shares)				6,941,352				6,941,352
Weighted average shares outstanding, diluted (in shares)				6,941,352				6,941,352
Basic net loss per share (in dollars per share)				$ (0.16)				$ (0.36)
Diluted net loss per share (in dollars per share)				$ (0.16)				$ (0.36)

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Share - Schedule of Excluded Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)			0
Common stock issued for exercise of stock options subject to nonrecourse promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	16,345,627	1,168,952	16,570,671
Common stock issued for early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	130,925	191,337	235,766	216,401
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	92,318,613	6,495,364	89,293,938
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	16,608,921	15,028,510	16,494,336	10,291,433
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,447,842	0	3,972,999	0
Warrants | Common Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,773,408	1,793,993	6,199,099	1,861,315
Warrants | Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	704,633	0	1,158,407
Common stock issued subject to vesting
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,754,756	0	961,130	0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	16.60%	(0.50%)	3.80%	(0.80%)
Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount	$ 3.1